CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty 2020 GI Fellow Board of Advisors CLDF Committees
Centers of Educational Expertise  
Live Events Slide Library Webcasts Abstract Library Committee Members Conference Highlights
 
NASH | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
 

Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354. Online ahead of print.

Sabine Kahl 1 2 3, Jennifer Pützer 1 2, Michael Roden 1 2 3
 
2.AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects
 

Sci Rep. 2021 Jul 21;11(1):14834. doi: 10.1038/s41598-021-94277-3.

Carlo De Matteis 1, Marica Cariello 1, Giusi Graziano 1, Stefano Battaglia 2 3, Patrizia Suppressa 2, Giuseppina Piazzolla 2, Carlo Sabbà 2, Antonio Moschetta 4 5
 
3.How will NAFLD change the liver transplant landscape in the 2020s?
 

Clin Res Hepatol Gastroenterol. 2021 Jul 23;101759.doi: 10.1016/j.clinre.2021.101759. Online ahead of print.

François Villeret 1, Jérôme Dumortier 2, Domitille Erard-Poinsot 3
 
4.Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications
 

Diabetes Obes Metab. 2021 Jul 29. doi: 10.1111/dom.14484. Online ahead of print.

Christopher D Byrne 1 2, Giovanni Targher 3
 
5.Maternal obesity increases the risk and severity of NAFLD in offspring
 

J Hepatol. 2021 Jul 18;S0168-8278(21)01899-7. doi: 10.1016/j.jhep.2021.06.045.Online ahead of print.

Hannes Hagström 1, Tracey G Simon 2, Bjorn Roelstraete 3, Olof Stephansson 4, Jonas Söderling 5, Jonas F Ludvigsson 6
 
6.Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology
 

J Hepatol. 2021 Jul 29;S0168-8278(21)01948-6. doi: 10.1016/j.jhep.2021.07.018.Online ahead of print.

Gennaro D'Amico 1, Luigi Maruzzelli 2, Aldo Airoldi 3, Ioannis Petridis 4, Giulia Tosetti 5, Antonio Rampoldi 6, Mario D'Amico 7, Roberto Miraglia 2, Stella De Nicola 3, Vincenzo La Mura 8, Marco Solcia 6, Riccardo Volpes 4, Giovanni Perricone 3, Cristiano Sgrazzutti 9, Angelo Vanzulli 9, Massimo Primignani 5, Angelo Luca 2, Giuseppe Malizia 10, Alessandro Federico 11, Marcello Dallio 11, Angelo Andriulli 12, Angelo Iacobellis 12, Luigi Addario 13, Matteo Garcovich 14, Antonio Gasbarrini 14, Luchino Chessa 15, Francesco Salerno 16, Giulia Gobbo 16, Manuela Merli 17, Lorenzo Ridola 18, Gianluca Svegliati Baroni 19, Giuseppe Tarantino 19, Nicola Caporaso 20, Filomena Morisco 20, Pietro Pozzoni 21, Agostino Colli 21, Luca Saverio Belli 3
 
7.Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
 

Clin Gastroenterol Hepatol. 2021 Jul 27;S1542-3565(21)00821-1. doi: 10.1016/j.cgh.2021.07.039.Online ahead of print.

Zobair M Younossi 1, Maria Stepanova 2, Rebecca A Taub 3, Jordan Mark Barbone 3, Stephen A Harrison 4
 
8.Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes
 

Liver Int. 2021 Jul 30. doi: 10.1111/liv.15025. Online ahead of print.

Jonathan B Steinman 1, Marcela A Salomao 2, Utpal B Pajvani 3
 
9.Diet and exercise in NAFLD/NASH: Beyond the obvious
 

Liver Int. 2021 Jul 30. doi: 10.1111/liv.15024. Online ahead of print.

Georg Semmler 1, Christian Datz 2, Thomas Reiberger 1, Michael Trauner 1
 
10.The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease
 

Curr Opin Infect Dis. 2021 Jul 15. doi: 10.1097/QCO.0000000000000759. Online ahead of print.

Jake S Jacob 1, Aijaz Ahmed, George Cholankeril
 
11.FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
 

Cell Metab. 2021 Aug 3;33(8):1671-1684.e4. doi: 10.1016/j.cmet.2021.06.012. Epub 2021 Jul 15.

Bethan L Clifford 1, Leslie R Sedgeman 1, Kevin J Williams 2, Pauline Morand 3, Angela Cheng 3, Kelsey E Jarrett 1, Alvin P Chan 1, Madelaine C Brearley-Sholto 1, Annika Wahlström 4, Julianne W Ashby 1, William Barshop 3, James Wohlschlegel 3, Anna C Calkin 5, Yingying Liu 6, Anders Thorell 7, Peter J Meikle 8, Brian G Drew 9, Julia J Mack 10, Hanns-Ulrich Marschall 4, Elizabeth J Tarling 11, Peter A Edwards 12, Thomas Q de Aguiar Vallim 13
 
12.Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease
 

Int J Eat Disord. 2021 Jul 17. doi: 10.1002/eat.23584. Online ahead of print.

Roberta Forlano 1, Christopher Harlow 1, Benjamin H Mullish 1, Mark R Thursz 1, Pinelopi Manousou 1, Michael Yee 2
 
13.Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study
 

Clin Gastroenterol Hepatol. 2021 Jul 13;S1542-3565(21)00747-3. doi: 10.1016/j.cgh.2021.07.016.Online ahead of print.

Omar T Ahmed 1, Tolga Gidener 1, Kristin C Mara 2, Joseph J Larson 2, Terry M Therneau 2, Alina M Allen 3
 
14.Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease
 

Surg Obes Relat Dis. 2021 Jun 29;S1550-7289(21)00264-1. doi: 10.1016/j.soard.2021.05.029.Online ahead of print

Christopher J Tignanelli 1, Carolyn T Bramante 2, Nirjhar Dutta 2, Leonardo Tamariz 3, Michael G Usher 2, Sayeed Ikramuddin 4
 
15.Bariatric surgery proves long-term benefit in patients with cirrhosis
 

Gastroenterol Rep (Oxf). 2020 Nov 24;9(3):252-256.doi: 10.1093/gastro/goaa057.eCollection 2021 Jun.

Manhal Izzy 1, Mounika Angirekula 2, Barham K Abu Dayyeh 2, Fateh Bazerbachi 3, Kymberly D Watt 2
 
16.Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children
 

J Clin Med. 2021 Jun 25;10(13):2812. doi: 10.3390/jcm10132812.

Cristina Bellarosa 1, Giorgio Bedogni 1, Annalisa Bianco 1 2, Sabrina Cicolini 3, Diana Caroli 3, Claudio Tiribelli 1, Alessandro Sartorio 3 4
 
17.Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan
 

Clin Gastroenterol Hepatol. 2021 Jun 29;S1542-3565(21)00693-5.doi: 10.1016/j.cgh.2021.06.029. Online ahead of print.

Donghee Kim 1, Peter Konyn 2, George Cholankeril 3, Aijaz Ahmed 4
 
18.The relationship between frailty and cirrhosis etiology: From the Functional Assessment in Liver Transplantation (FrAILT) Study
 

Liver Int. 2021 Jul 5.doi: 10.1111/liv.15006. Online ahead of print.

Chelsea Q Xu 1, Yara Mohamad 1, Matthew R Kappus 2, Brian Boyarsky 3, Daniel R Ganger 4, Michael L Volk 5, Robert S Rahimi 6, Andres Duarte-Rojo 7, Mara McAdams-DeMarco 3 8, Dorry L Segev 3 8, Daniela P Ladner 9 10, Elizabeth C Verna 11, Joshua Grab 12, Monica Tincopa 13, Michael A Dunn 7, Jennifer C Lai 1
 
19.Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
 

Front Endocrinol (Lausanne). 2021 Jun 17;12:635556. doi: 10.3389/fendo.2021.635556.eCollection 2021.

Qiong Wei 1 2, Xinyue Xu 1 2, Li Guo 1 2, Jia Li 3, Ling Li 1 2
 
20.Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study
 

Diagnostics (Basel). 2021 Jun 13;11(6):1083. doi: 10.3390/diagnostics11061083.

Nuria Perez-Diaz-Del-Campo 1 2, Jose I Riezu-Boj 2 3, Bertha Araceli Marin-Alejandre 1 2, J Ignacio Monreal 3 4, Mariana Elorz 3 5, José Ignacio Herrero 3 6 7, Alberto Benito-Boillos 3 5, Fermín I Milagro 1 2 3 8, Josep A Tur 8 9, Itziar Abete 1 2 3 8, M Angeles Zulet 1 2 3 8, J Alfredo Martinez 1 2 3 8
 
21.Embedding assessment of liver fibrosis into routine diabetic review in primary care
 

HEP Rep. 2021 Apr 22;3(4):100293. doi: 10.1016/j.jhepr.2021.100293. eCollection 2021 Aug.

Dina Mansour 1 2, Allison Grapes 1, Marc Herscovitz 3, Paul Cassidy 4, Jonathan Vernazza 1, Andrea Broad 5, Quentin M Anstee 2 6, Stuart McPherson 2 6
 
22.Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
 

J Clin Endocrinol Metab. 2021 Jun 30;dgab417. doi: 10.1210/clinem/dgab417.Online ahead of print.

Fernando Bril 1 2, Michael J McPhaul 3, Srilaxmi Kalavalapalli 2, Romina Lomonaco 2, Diana Barb 2, Meagan E Gray 4, Dov Shiffman 3, Charles M Rowland 3, Kenneth Cusi 2 5
 
23.Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
 

BMJ Open Gastroenterol. 2021 Jun;8(1):e000634. doi: 10.1136/bmjgast-2021-000634.

Monica A Tincopa 1, Jane Wong 2, Michael Fetters 3, Anna S Lok 2
 
24.NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040
 

Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032. Online ahead of print.

Jennifer A Flemming 1 2 3 4, Maya Djerboua 2, Patti A Groome 2 3 4, Christopher M Booth 2 3 4, Norah A Terrault 5
 
25.TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial
 

Gastroenterology. 2021 Jul 20;S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.Online ahead of print.

Rohit Loomba 1, Rizwana Mohseni 2, K Jean Lucas 3, Julio A Gutierrez 4, Robert G Perry 5, James F Trotter 6, Robert S Rahimi 6, Stephen A Harrison 7, Veeral Ajmera 8, Jeffrey D Wayne 9, Marie O'Farrell 10, William McCulloch 10, Katharine Grimmer 10, Mary Rinella 11, Vincent Wai-Sun Wong 12, Vlad Ratziu 13, Gregory J Gores 14, Brent A Neuschwander-Tetri 15, George Kemble 10
 
26.Preparing for the NASH epidemic: A call to action
 

Metabolism. 2021 Jul 6;154822. doi: 10.1016/j.metabol.2021.154822. Online ahead of print.

Fasiha Kanwal 1, Jay H Shubrook 2, Zobair Younossi 3, Yamini Natarajan 4, Elisabetta Bugianesi 5, Mary E Rinella 6, Stephen A Harrison 7, Christos Mantzoros 8, Kim Pfotenhauer 9, Samuel Klein 10, Robert H Eckel 11, Davida Kruger 12, Hashem El-Serag 4, Kenneth Cusi 13
 
27.Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches
 

Nutrients. 2021 Jun 8;13(6):1977. doi: 10.3390/nu13061977.

Angelo Armandi 1 2, Jörn M Schattenberg 2 3
 
28.Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm
 

Rom J Morphol Embryol. Oct-Dec 2020;61(4):1023-1031. doi: 10.47162/RJME.61.4.04.

Laura Mihaela Trandafir 1, Otilia Elena Frasinariu, Maria Magdalena Leon-Constantin, Stefan Chiriac, Mioara Florentina Trandafirescu, Ingrith Crenguta Miron, Alina Costina Luca, Alin Constantin Iordache, Elena Cojocaru
 
29.Conventional ultrasound for diagnosis of hepatic steatosis is better than believed
 

Z Gastroenterol. 2021 Jun 25. doi: 10.1055/a-1491-1771. Online ahead of print.

Christoph F Dietrich 1, Long Shi 2, Axel Löwe 1, Yi Dong 3, Andrej Potthoff 4, Zeno Sparchez 5, Andreas Teufel 6, Sabine Guth 7, Jonas Koch 1, Richard G Barr 8, Xin-Wu Cui 9
 
30.Defining comprehensive models of care for NAFLD
 

Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.Online ahead of print.

Jeffrey V Lazarus 1 2, Quentin M Anstee 3 4, Hannes Hagström 5, Kenneth Cusi 6, Helena Cortez-Pinto 7, Henry E Mark 8, Michael Roden 9 10 11, Emmanuel A Tsochatzis 12 13, Vincent Wai-Sun Wong 14, Zobair M Younossi 15, Shira Zelber-Sagi 16 17, Manuel Romero-Gómez # 18, Jörn M Schattenberg # 19
 
31.Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease
 

Dig Dis Sci. 2021 Jun 26;1-7. doi: 10.1007/s10620-021-07120-0. Online ahead of print.

Mohamed A Elfeki 1 2 3, Julian Robles 1 2, Zaheer Akhtar 1 2, Fauzia Ullah 1 2, Ice Ganapathiraju 1 2, Calvin Tran 4 5, Casey Inman 4 5, Simon M Collin 6, Rossana Rosa 7
 
32.COVID-19 and pediatric fatty liver disease: Is there interplay?
 

World J Gastroenterol. 2021 Jun 14;27(22):3064-3072.doi: 10.3748/wjg.v27.i22.3064.

Anna Di Sessa 1, Francesca Lanzaro 2, Sarah Zarrilli 2, Vittorio Picone 2, Stefano Guarino 2, Emanuele Miraglia Del Giudice 2, Pierluigi Marzuillo 2
 
33.Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
 

Hepatol Commun. 2021 May 12;5(7):1201-1211. doi: 10.1002/hep4.1710. eCollection 2021 Jul.

Zobair M Younossi 1 2, Maria Stepanova 3, Mazen Noureddin 4, Kris V Kowdley 5, Simone I Strasser 6, Anita Kohli 7, Peter Ruane 8, Mitchell L Shiffman 9, Aasim Sheikh 10, Nadege Gunn 11, Stephen H Caldwell 12, Ryan S Huss 13, Robert P Myers 13, Vincent Wai-Sun Wong 14, Naim Alkhouri 15, Zachary Goodman 1 2, Rohit Loomba 4
 
34.Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
 

Clin Gastroenterol Hepatol. 2021 Jul 15;S1542-3565(21)00751-5. doi: 10.1016/j.cgh.2021.07.020.Online ahead of print.

Zobair M Younossi 1, Maria Stepanova 2, Fatema Nader 2, Rohit Loomba 3, Quentin M Anstee 4, Vlad Ratziu 5, Stephen Harrison 6, Arun J Sanyal 7, Jörn M Schattenberg 8, A Sidney Barritt 9, Mazen Noureddin 10, Martin Bonacci 11, Gail Cawkwell 11, Bruce Wong 11, Mary Rinella 12, REGENERATE Study Investigators
 
35.Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm
 

Rom J Morphol Embryol. Oct-Dec 2020;61(4):1023-1031. doi: 10.47162/RJME.61.4.04.

Laura Mihaela Trandafir 1, Otilia Elena Frasinariu, Maria Magdalena Leon-Constantin, Stefan Chiriac, Mioara Florentina Trandafirescu, Ingrith Crenguta Miron, Alina Costina Luca, Alin Constantin Iordache, Elena Cojocaru
 
36.Conventional ultrasound for diagnosis of hepatic steatosis is better than believed
 

Z Gastroenterol. 2021 Jun 25. doi: 10.1055/a-1491-1771. Online ahead of print.

Christoph F Dietrich 1, Long Shi 2, Axel Löwe 1, Yi Dong 3, Andrej Potthoff 4, Zeno Sparchez 5, Andreas Teufel 6, Sabine Guth 7, Jonas Koch 1, Richard G Barr 8, Xin-Wu Cui 9
 
37.Defining comprehensive models of care for NAFLD
 

Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.Online ahead of print.

Jeffrey V Lazarus 1 2, Quentin M Anstee 3 4, Hannes Hagström 5, Kenneth Cusi 6, Helena Cortez-Pinto 7, Henry E Mark 8, Michael Roden 9 10 11, Emmanuel A Tsochatzis 12 13, Vincent Wai-Sun Wong 14, Zobair M Younossi 15, Shira Zelber-Sagi 16 17, Manuel Romero-Gómez # 18, Jörn M Schattenberg # 19
 
38.Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease
 

Dig Dis Sci. 2021 Jun 26;1-7. doi: 10.1007/s10620-021-07120-0. Online ahead of print.

Mohamed A Elfeki 1 2 3, Julian Robles 1 2, Zaheer Akhtar 1 2, Fauzia Ullah 1 2, Ice Ganapathiraju 1 2, Calvin Tran 4 5, Casey Inman 4 5, Simon M Collin 6, Rossana Rosa 7
 
39.COVID-19 and pediatric fatty liver disease: Is there interplay?
 

World J Gastroenterol. 2021 Jun 14;27(22):3064-3072.doi: 10.3748/wjg.v27.i22.3064.

Anna Di Sessa 1, Francesca Lanzaro 2, Sarah Zarrilli 2, Vittorio Picone 2, Stefano Guarino 2, Emanuele Miraglia Del Giudice 2, Pierluigi Marzuillo 2
 
40.Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis
 

JGH Open. 2021 Jun 1;5(7):740-749. doi: 10.1002/jgh3.12575. eCollection 2021 Jul.

Beth A Davison 1 2, Christopher Edwards 1, Rohit Loomba 3, Stephen A Harrison 4, Gad Cotter 1 2, Naim Alkhouri 5, Gary G Koch 6, Howard C Dittrich 7
 
41.Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases
 

Semin Liver Dis. 2021 Jul 9. doi: 10.1055/s-0041-1731705. Online ahead of print.

Yuly P Mendoza 1 2 3, Chiara Becchetti 1 2, Kymberly D Watt 4, Annalisa Berzigotti 1 2
 
42.Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
 

Int J Obes (Lond). 2021 Jun 24. doi: 10.1038/s41366-021-00881-8. Online ahead of print.

Andreas Drolz # 1, Stefan Wolter # 2, Malte H Wehmeyer 3, Felix Piecha 3, Thomas Horvatits 3, Julian Schulze Zur Wiesch 3, Ansgar W Lohse 3, Oliver Mann 2, Johannes Kluwe 3
 
43.Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?
 

Liver Int. 2021 Jun;41 Suppl 1:105-111. doi: 10.1111/liv.14846.

Benjamin Schröder 1 2, Sabine Kahl 1 2, Michael Roden 1 2 3
 
44.Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation
 

Sci Rep. 2021 Jun 23;11(1):13159. doi: 10.1038/s41598-021-92264-2.

Victoria L Slaughter 1, John W Rumsey 2, Rachel Boone 1, Duaa Malik 1, Yunqing Cai 2, Narasimhan Narasimhan Sriram 2, Christopher J Long 2, Christopher W McAleer 2, Stephen Lambert 3, Michael L Shuler 2, J J Hickman 4 5
 
45.Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap
 

Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025. Online ahead of print.

George Cholankeril 1, Fasiha Kanwal 1 2
 
46.COVID-19 and the liver - Lessons learned
 

Liver Int. 2021 Jun;41 Suppl 1:1-8. doi: 10.1111/liv.14854.

Toni Herta 1 2, Thomas Berg 1
 
47.Anti-diabetic drugs and NASH: from current options to promising perspectives
 

Expert Opin Investig Drugs. 2021 Jul 12;1-13. doi: 10.1080/13543784.2021.1951701.Online ahead of print.

Sarra Smati 1, Clémence M Canivet 2 3, Jérôme Boursier 2 3, Bertrand Cariou 1
 
48.PPAR-?-induced Changes in Visceral Fat and Adiponectin Levels are Associated with Improvement of Steatohepatitis in Patients with NASH
 

Liver Int. 2021 Jul 5. doi: 10.1111/liv.15005. Online ahead of print.

Amalia Gastaldelli 1 2, Silvia Sabatini 2 3, Fabrizia Carli 2, Melania Gaggini 2, Fernando Bril 4, Renata Belfort-DeAguiar 5, Vincenzo Positano 6, Diana Barb 4, Sushma Kadiyala 4 7, Stephen Harrison 8, Kenneth Cusi 4 7
 
49.Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
 

Nat Med. 2021 Jul;27(7):1262-1271. doi: 10.1038/s41591-021-01425-3. Epub 2021 Jul 8.

Stephen A Harrison 1, Peter J Ruane 2, Bradley L Freilich 3, Guy Neff 4, Rashmee Patil 5, Cynthia A Behling 6, Chen Hu 7, Erica Fong 8, Brittany de Temple 8, Erik J Tillman 8, Timothy P Rolph 8, Andrew Cheng 8, Kitty Yale 9
 
50.A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease
 

Clin Obes. 2021 Jun 9;e12472. doi: 10.1111/cob.12472. Online ahead of print.

Sakil Kulkarni 1, Nadia Naz 1, Hongjie Gu 2, Janis M Stoll 1, Michael D Thompson 1 3, Brian J DeBosch 1 3 4
 
51.Copper nutrition and biochemistry and human (patho)physiology
 

Adv Food Nutr Res. 2021;96:311-364. doi: 10.1016/bs.afnr.2021.01.005. Epub 2021 Apr 12.

James F Collins 1

 
 
52.Towards collaborative management of nonalcoholic fatty liver disease (TCM-NAFLD): a 'real-world' pathway for fibrosis risk assessment in primary care
 

Intern Med J. 2021 Jun 17. doi: 10.1111/imj.15422. Online ahead of print.

Kelly L Hayward 1 2, Benjamin J McKillen 1 2, Leigh U Horsfall 1 2, Carolyn McIvor 3, Katerina Liew 3, Jo Sexton 3, Amy L Johnson 1 2, Katharine M Irvine 1 4, Patricia C Valery 1 5, Steven M McPhail 6 7, Laurence J Britton 2 8, William Rosenberg 9 10, Ingrid Weate 11, Sue Williams 12, Elizabeth E Powell 1 2
 
53.Nonalcoholic fatty liver disease is associated with a higher incidence of coeliac disease
 

Eur J Gastroenterol Hepatol. 2021 Jun 17. doi: 10.1097/MEG.0000000000002234.Online ahead of print.

Christoph Roderburg 1, Sven Loosen, Karel Kostev, Münevver Demir, Markus S Joerdens, Tom Luedde
 
54.Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand
 

Cureus. 2021 May 5;13(5):e14858. doi: 10.7759/cureus.14858.

Rajvi Gor 1, Nabeel A Siddiqui 1, Ransirini Wijeratne Fernando 1, Archana Sreekantan Nair 1, Janan Illango 1, Mushrin Malik 1, Pousette Hamid 2
 
55.Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
 

J Pers Med. 2021 Jun 2;11(6):499. doi: 10.3390/jpm11060499.

Michele Finotti 1, Maurizio Romano 1, Pasquale Auricchio 2, Michele Scopelliti 1, Marco Brizzolari 1, Ugo Grossi 1, Marco Piccino 1, Stefano Benvenuti 3, Giovanni Morana 4, Umberto Cillo 2, Giacomo Zanus 1
 
56.Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2021 Jun 10;10(12):2565. doi: 10.3390/jcm10122565.

Ilkay S Idilman 1 2, Hsien Min Low 1 3, Tolga Gidener 1, Kenneth Philbrick 1, Taofic Mounajjed 4, Jiahui Li 1, Alina M Allen 5, Meng Yin 1, Sudhakar K Venkatesh 1
 
57.Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis
 

Br J Clin Pharmacol. 2021 Jun 16. doi: 10.1111/bcp.14943. Online ahead of print.

Daniele Pastori 1, Arianna Pani 2, Arianna Di Rocco 3, Danilo Menichelli 1, Gianluca Gazzaniga 2, Alessio Farcomeni 4, Laura D'Erasmo 5, Francesco Angelico 3, Maria Del Ben 1, Francesco Baratta 1
 
58.Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease
 

J Hepatol. 2021 Jun 11;S0168-8278(21)00402-5.doi: 10.1016/j.jhep.2021.05.029.Online ahead of print.

Carolin Lackner 1, Rudolf E Stauber 2, Susan Davies 3, Helmut Denk 4, Hans Peter Dienes 5, Viviane Gnemmi 6, Maria Guido 7, Rosa Miquel 8, Valerie Paradis 9, Peter Schirmacher 10, Luigi Terracciano 11, Andrea Berghold 12, Gudrun Pregartner 12, Lukas Binder 2, Philipp Douschan 2, Florian Rainer 2, Stephan Sygulla 4, Marion Jager 13, Pierre-Emmanuel Rautou 13, Andreea Bumbu 14, Adelina Horhat 14, Ioana Rusu 15, Horia Stefanescu 14, Sönke Detlefsen 16, Aleksander Krag 17, Maja Thiele 17, Helena Cortez-Pinto 18, Christophe Moreno 19, Annette S H Gouw 20, Dina G Tiniakos 21
 
59.Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
 

Nat Rev Endocrinol. 2021 Aug;17(8):484-495. doi: 10.1038/s41574-021-00507-z.Epub 2021 Jun 15.

Daniel Ferguson 1, Brian N Finck 2
 
60.Serum Alanine Transaminase Is an Inadequate Nonalcoholic Fatty Liver Screening Test in Adolescents: Results From the National Health and Nutrition Examination Survey 2017-2018
 

Clin Pediatr (Phila). 2021 Jul;60(8):370-375. doi: 10.1177/00099228211020177.

Gary A Abrams 1, Anna M Rabil 2, Ana-Ysabel P Williams 2, Eric M Hecht 2 3 4
 
61.Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
 

Cureus. 2021 May 20;13(5):e15141. doi: 10.7759/cureus.15141.

Haider Ghazanfar 1, Sameer D Kandhi 1, Iqra Nawaz 1, Nismat Javed 2, Minu C Abraham 1, Mohamed Farag 1, Jaydeep Mahasamudram 1, Vishwa B Patel 3, Faryal Altaf 4, Harish Patel 5
 
62.Saroglitazar for the treatment of NASH: the PPAR story goes on!
 

Hepatology. 2021 Jun 23. doi: 10.1002/hep.32024. Online ahead of print.

Sven Ma Francque 1 2 3 4
 
63.Current management of NAFLD/NASH
 

Liver Int. 2021 Jun;41 Suppl 1:89-94. doi: 10.1111/liv.14869.

Ana Carolina Cardoso 1, Claudio de Figueiredo-Mendes 2, Cristiane A Villela-Nogueira 1
 
64.New drugs for NASH
 

Liver Int. 2021 Jun;41 Suppl 1:112-118. doi: 10.1111/liv.14844.

Somaya A M Albhaisi 1, Arun J Sanyal 2
 
65.Management of NAFLD patients with advanced fibrosis
 

Liver Int. 2021 Jun;41 Suppl 1:95-104. doi: 10.1111/liv.14847.

Douglas Maya-Miles 1 2 3, Javier Ampuero 1 2 3 4, Rocío Gallego-Durán 1 2 3, Paola Dingianna 2, Manuel Romero-Gómez 1 2 3 4
 
66.Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort
 

Eur J Clin Invest. 2021 Jun 13;e13627. doi: 10.1111/eci.13627. Online ahead of print.

Adrian Post 1, Erwin Garcia 2, Eline H van den Berg 3, Jose L Flores-Guerrero 1, Eke G Gruppen 1, Dion Groothof 1, Berend Daan Westenbrink 4, Margery A Connelly 2, Stephan J L Bakker 1, Robin P F Dullaart 1
 
67.Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
 

Hepatology. 2021 Jun 15. doi: 10.1002/hep.32012. Online ahead of print.

Judith van Dalem 1 2, Johanna H M Driessen 1 2 3 4, Andrea M Burden 5, Coen D A Stehouwer 2 6, Olaf H Klungel 3, Frank de Vries 1 2 3, Martijn C G J Brouwers 2 7
 
68.Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
 

J Intern Med. 2021 Jun 12. doi: 10.1111/joim.13343. Online ahead of print.

Hannes Hagström 1 2 3, Stergios Kechagias 4, Mattias Ekstedt 4, From the symposium: Non-Alcoholic Fatty Liver Disease (NAFLD)
 
69.Natural history of NASH
 

Liver Int. 2021 Jun;41 Suppl 1:78-82. doi: 10.1111/liv.14910.

Angelo Armandi 1, Elisabetta Bugianesi 1
 
70.Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study
 

Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

A Sidney Barritt 1, Stephanie Watkins 2, Norman Gitlin 3, Samuel Klein 4, Anna S Lok 5, Rohit Loomba 6, Cheryl Schoen 2, K Rajender Reddy 7, Huy Ngoc Trinh 8, Andrea R Mospan 2, Miriam B Vos 9, L Michael Weiss 10, Kenneth Cusi 11, Brent A Neuschwander-Tetri 12, Arun J Sanyal 13
 
71.The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease
 

Int J Mol Sci. 2021 May 15;22(10):5239. doi: 10.3390/ijms22105239.

Laia Bertran 1, Angela Pastor 1, Marta Portillo-Carrasquer 1, Jessica Binetti 2, Carmen Aguilar 1, Salomé Martínez 3, Margarita Vives 4, Fàtima Sabench 4, José Antonio Porras 2, David Riesco 2, Daniel Del Castillo 4, Cristóbal Richart 1 2, Teresa Auguet 1 2
 
72.Animal Fat Intake Is Associated with Albuminuria in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome
 

Nutrients. 2021 May 4;13(5):1548. doi: 10.3390/nu13051548.

Manuela Abbate 1 2, Catalina M Mascaró 1 2, Sofía Montemayor 1 2, María Barbería-Latasa 3, Miguel Casares 4, Cristina Gómez 5, Lucia Ugarriza 1 2 6, Silvia Tejada 1 2 7, Itziar Abete 7 8, María Ángeles Zulet 7 8, Antoni Sureda 1 2 7, J Alfredo Martínez 7 8 9, Josep A Tur 1 2 7
 
73.Psoriasis and Liver Damage in HIV-Infected Patients
 

Cells. 2021 May 4;10(5):1099. doi: 10.3390/cells10051099.

Carmen Busca Arenzana 1, Lucía Quintana Castanedo 2, Clara Chiloeches Fernández 2, Daniel Nieto Rodríguez 2, Pedro Herranz Pinto 2, Ana Belén Delgado Hierro 1, Antonio Olveira Martín 3, María Luisa Montes Ramírez 1
 
74.Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
 

Cancers (Basel). 2021 May 11;13(10):2305. doi: 10.3390/cancers13102305.

Gian Paolo Caviglia 1, Angelo Armandi 1, Chiara Rosso 1, Silvia Gaia 2, Serena Aneli 1 3, Emanuela Rolle 2, Maria Lorena Abate 1, Antonella Olivero 1, Aurora Nicolosi 1, Marta Guariglia 1, Davide Giuseppe Ribaldone 1, Patrizia Carucci 2, Giorgio Maria Saracco 1 2, Elisabetta Bugianesi 1 2
 
75.Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review
 

Int J Mol Sci. 2021 May 1;22(9):4807. doi: 10.3390/ijms22094807.

Raquel Cano 1, José L Pérez 1, Lissé Angarita Dávila 2, Ángel Ortega 1, Yosselin Gómez 1, Nereida Josefina Valero-Cedeño 3, Heliana Parra 1, Alexander Manzano 1, Teresa Isabel Véliz Castro 3, María P Díaz Albornoz 1, Gabriel Cano 4, Joselyn Rojas-Quintero 5, Maricarmen Chacín 6, Valmore Bermúdez 6
 
76.Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk
 

Am J Physiol Gastrointest Liver Physiol. 2021 Jun 16. doi: 10.1152/ajpgi.00058.2021.Online ahead of print.

Graciela E Delgado 1, Marcus E Kleber 1 2, Angela P Moissl 1 3 4, Babak Yazdani 1, Alexander Kusnik 5 6, Matthias P Ebert 5 6, Winfried März 1 7, Bernhard K Krämer 1 6, Alexander Lammert 1 8, Andreas Teufel 5 6
 
77.Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH
 

Mol Metab. 2021 Jun 9;101270. doi: 10.1016/j.molmet.2021.101270. Online ahead of print.

Gavin Fredrickson 1, Fanta Barrow 1, Katrina Dietsche 1, Preethy Parthiban 1, Saad Khan 2, Sacha Robert 1, Maya Demirchian 1, Hailey Rhoades 1, Haiguang Wang 1, Oyedele Adeyi 3, Xavier S Revelo 4
 
78.Update on cardiovascular risk in nonalcoholic fatty liver disease
 

Curr Opin Cardiol. 2021 Jul 1;36(4):478-486.doi: 10.1097/HCO.0000000000000861.

Michael P Johnston 1, Janisha Patel 2, Christopher D Byrne 3 4
 
79.PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity
 

Nutrients. 2021 May 12;13(5):1621. doi: 10.3390/nu13051621.

Roshonda B Jones 1, Lide Arenaza 2, Claudia Rios 1, Jasmine F Plows 1, Paige K Berger 1, Tanya L Alderete 3, Jennifer L Fogel 1, Krishna Nayak 4, Passant Mohamed 5, Darryl Hwang 5, Suzanne Palmer 5, Frank Sinatra 1, Hooman Allayee 6, Rohit Kohli 1, Michael I Goran 1
 
80.FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
 

J Clin Med. 2021 May 29;10(11):2415. doi: 10.3390/jcm10112415.

Yasaman Vali 1, Jenny Lee 1, Jérôme Boursier 2 3, René Spijker 4 5, Joanne Verheij 6, M Julia Brosnan 7, Quentin M Anstee 8 9, Patrick M Bossuyt 1, Mohammad Hadi Zafarmand 1, On Behalf Of The Litmus Systematic Review Team
 
81.Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes
 

BMJ Open Diabetes Res Care. 2021 May;9(1):e002243. doi: 10.1136/bmjdrc-2021-002243.

Sven H Loosen 1, Münevver Demir 1, Anselm Kunstein 1, Markus Jördens 1, Natalia Qvarskhava 1, Mark Luedde 1, Tom Luedde 1, Christoph Roderburg 2, Karel Kostev 3
 
82.The placebo response in randomised trials in nonalcoholic steatohepatitis simply explained
 

Clin Gastroenterol Hepatol. 2021 Jun 3;S1542-3565(21)00598-X. doi: 10.1016/j.cgh.2021.05.059.Online ahead of print.

Ian A Rowe 1, Richard Parker 2
 
83.Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
 

J Hepatol. 2021 Jun 3;S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.Online ahead of print.

Ramy Younes 1, Gian Paolo Caviglia 2, Olivier Govaere 3, Chiara Rosso 2, Angelo Armandi 2, Tiziana Sanavia 2, Grazia Pennisi 4, Antonio Liguori 5, Paolo Francione 6, Rocío Gallego-Durán 7, Javier Ampuero 7, Maria J Garcia Blanco 8, Rocio Aller 9, Dina Tiniakos 10, Alastair Burt 3, Ezio David 11, Fabio M Vecchio 12, Marco Maggioni 13, Daniela Cabibi 14, María Jesús Pareja 15, Marco Y W Zaki 16, Antonio Grieco 17, Anna L Fracanzani 6, Luca Valenti 18, Luca Miele 17, Piero Fariselli 2, Salvatore Petta 4, Manuel Romero-Gomez 7, Quentin M Anstee 19, Elisabetta Bugianesi 20
 
84.Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease
 

 Liver Int. 2021 May 16. doi: 10.1111/liv.14963. Online ahead of print.

Jose L Flores-Guerrero 1, Adrian Post 1, Peter R van Dijk 2, Margery A Connelly 3, Erwin Garcia 3, Gerjan Navis 1, Stephan J L Bakker 1, Robin P F Dullaart 2
 
85.The role of elastography in non-alcoholic fatty liver disease
 

Minerva Gastroenterol (Torino). 2021 Jun;67(2):164-170. doi: 10.23736/S2724-5985.21.02801-4.

Antonio Liguori 1, Maria E Ainora 1, Laura Riccardi 1, Nicoletta DE Matthaeis 1, Fabrizio Pizzolante 1, Antonio Gasbarrini 1 2, Maria A Zocco 1 2, Antonio Grieco 1 2, Gianludovico Rapaccini 1 2, Luca Miele 3 2
 
86.Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population
 

Clin Gastroenterol Hepatol. 2021 May 25;S1542-3565(21)00573-5.doi: 10.1016/j.cgh.2021.05.035. Online ahead of print.

Scott McHenry 1, Yikyung Park 2, Nicholas O Davidson 3
 
87.Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes
 

PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449. eCollection 2021.

Kristin Alexandra Dayton 1, Fernando Bril 2 3, Diana Barb 2, Jinping Lai 4, Srilaxmi Kalavalapalli 2, Kenneth Cusi 2 3
 
88.Step by Step: Managing the Complications of Cirrhosis
 

Hepat Med. 2021 May 25;13:45-57.doi: 10.2147/HMER.S278032. eCollection 2021.

Irene Perez 1, Fabian J Bolte 1, William Bigelow 1, Zachary Dickson 2, Neeral L Shah 2
 
89.Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis
 

Radiology. 2021 Jun 1;204325. doi: 10.1148/radiol.2021204325. Online ahead of print.

Hanyu Jiang 1, Hubert C Chen 1, Kyle J Lafata 1, Mustafa R Bashir 1
 
90.Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis
 

Cochrane Database Syst Rev. 2021 Jun 11;6:CD013156.doi: 10.1002/14651858.CD013156.pub2.

Elena Buzzetti 1, Audrey Linden 2, Lawrence Mj Best 2, Angela M Madden 3, Danielle Roberts 2, Thomas J G Chase 4, Suzanne C Freeman 5, Nicola J Cooper 5, Alex J Sutton 5, Dominic Fritche 6, Elisabeth Jane Milne 7, Kathy Wright 8, Chavdar S Pavlov 9, Brian R Davidson 2, Emmanuel Tsochatzis 1, Kurinchi Selvan Gurusamy 2 9
 
91.Infections at the nexus of metabolic-associated fatty liver disease
 

Arch Toxicol. 2021 May 24;1-19. doi: 10.1007/s00204-021-03069-1.Online ahead of print.

Joost Boeckmans 1 2, Matthias Rombaut 3, Thomas Demuyser 4 5, Baptist Declerck 4, Denis Piérard 4, Vera Rogiers 3, Joery De Kock 3, Luc Waumans 6, Koen Magerman 6 7, Reinoud Cartuyvels 6, Jean-Luc Rummens 6, Robim M Rodrigues # 8, Tamara Vanhaecke # 3
 
92.Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival
 

Dig Dis Sci. 2021 May 23. doi: 10.1007/s10620-021-07048-5. Online ahead of print.

Kanokwan Pinyopornpanish 1 2, Wael Al-Yaman 3, Srinivasan Dasarathy 3 4, Carlos Romero-Marrero 3, Arthur McCullough 3 4
 
93.The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017
 

Hepatol Commun. 2021 Jan 14;5(5):749-759. doi: 10.1002/hep4.1673. eCollection 2021 May.

James M Paik 1, Pegah Golabi 1, Youssef Younossi 2, Nazaneen Saleh 1, Annan Nhyira 1, Zobair M Younossi 1 3
 
94.Discovery of novel modulators for the PPARa (peroxisome proliferator activated receptor a): Potential therapies for nonalcoholic fatty liver disease
 

Bioorg Med Chem. 2021 May 1;41:116193. doi: 10.1016/j.bmc.2021.116193. Online ahead of print.

 

Donna D Yu 1, Gregg Van Citters 2, Hongzhi Li 3, Brian M Stoltz 4, Barry M Forman 3
 
95.The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age
 

Hepatol Commun. 2021 Feb 6;5(5):891-905. doi: 10.1002/hep4.1681. eCollection 2021 May.

Patricia C Valery 1, Christina M Bernardes 1, Benjamin Mckillen 2 3, Samath Amarasena 4, Katherine A Stuart 2, Gunter Hartel 1, Paul J Clark 2 5, Richard Skoien 4, Tony Rahman 6, Leigh Horsfall 2 3, Kelly Hayward 2 3, Rohit Gupta 6, Andrew Lee 5, Leshni Pillay 7, Elizabeth E Powell 2 3
 
96.Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting
 

PLoS One. 2021 May 21;16(5):e0251741. doi: 10.1371/journal.pone.0251741. eCollection 2021.

Stephen E Congly 1 2, Abdel Aziz Shaheen 1 3, Mark G Swain 1
 
97.Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial
 

Hepatol Commun. 2021 Feb 5;5(5):786-797. doi: 10.1002/hep4.1680. eCollection 2021 May.

Samer Gawrieh 1, Laura A Wilson 2, Katherine P Yates 2, Oscar W Cummings 3, Eduardo Vilar-Gomez 1, Veeral Ajmera 4, Kris V Kowdley 5, William M Rosenberg 6, James Tonascia 2, Naga Chalasani 1
 
98.Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
 

World J Gastroenterol. 2021 May 21;27(19):2281-2298.doi: 10.3748/wjg.v27.i19.2281.

Lukas Hartl 1, Joshua Elias 2, Gerhard Prager 3, Thomas Reiberger 1, Lukas W Unger 4
 
99.coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
 

Hepatol Commun. 2021 Feb 12;5(5):774-785. doi: 10.1002/hep4.1678. eCollection 2021 May.

Elizabeth Clearfield 1, Veronica Miller 2, Joseph Nadglowski 3, Katherine Barradas 2, Jennifer Al Naber 1, Arun J Sanyal 4, Brent A Neuschwander-Tetri 5, Donna A Messner 1, coreNASH Panel

Collaborators,

Collaborators

  • coreNASH Panel: 

William Baldyga, Maria-Magdalena Balp, Catherine Brun-Strang, Robyn Carson, Wayne Eskridge, Kurinchi Gurusamy, Lars Hansen, Morten Hansen, Katy Harrison, Andras Harsanyi, Anders Hvelplund, Zoltán Kaló, Marko Korenjak, E J Milne, Euan McLeod, Michelle Mocarski, Joachim Musaeus, Fady Ntanios, Mazen Noureddin, Daniel Ollendorf, Jan Oscarsson, Stephen Rossi, Vlad Ratziu, Yaron Rotman, Leonardo Ruiz-Casas, Lewis Sandy, Jörn M Schattenberg, Mohammad Shadab Siddiqui, Gregory Steinberg, Ethan Weiss, Keith White, José Willemse, Kathy Wright, Michael Zemel
 
100.Non-alcoholic fatty liver diseases: current challenges and future directions
 

Ann Transl Med. 2021 Apr;9(8):726. doi: 10.21037/atm-20-3760.

Elke Roeb 1
 
101.Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality
 

J Clin Endocrinol Metab. 2021 May 13;dgab339. doi: 10.1210/clinem/dgab339.Online ahead of print.

Georg Semmler 1 2, Sarah Wernly 1, Sebastian Bachmayer 1, Isabella Leitner 1, Bernhard Wernly 3, Matthias Egger 1, Lena Schwenoha 1, Leonora Datz 1, Lorenz Balcar 1 2, Marie Semmler 1, Felix Stickel 4, David Niederseer 5, Elmar Aigner 6, Christian Datz 1
 
102.Obesity Management of Liver Transplant Waitlist Candidates and Recipients
 

Clin Liver Dis. 2021 Feb;25(1):1-18. doi: 10.1016/j.cld.2020.08.001.Epub 2020 Oct 12.

Danielle Brandman 1
 
103.Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
 

Liver Int. 2021 May 12. doi: 10.1111/liv.14943. Online ahead of print.

Patrizia Burra 1, Debora Bizzaro 1, Anna Gonta 1, Sarah Shalaby 1, Martina Gambato 1, Maria Cristina Morelli 2, Silvia Trapani 3, Annarosa Floreani 4 5, Fabio Marra 6, Maurizia Rossana Brunetto 7, Gloria Taliani 8, Erica Villa 9, Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF)
 
104.The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis
 

Hepatology. 2021 May 6. doi: 10.1002/hep.31886. Online ahead of print.

Laura E Dichtel 1
 
105.Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors
 

Exp Biol Med (Maywood). 2021 May 6;15353702211009228. doi: 10.1177/15353702211009228.Online ahead of print.

Manush Saydmohammed 1, Anupma Jha 1, Vineet Mahajan 1, Dillon Gavlock 1, Tong Ying Shun 1, Richard DeBiasio 1, Daniel Lefever 1, Xiang Li 1, Celeste Reese 1, Erin E Kershaw 2, Vijay Yechoor 2, Jaideep Behari 3 4, Alejandro Soto-Gutierrez 5 6, Larry Vernetti 1 7, Andrew Stern 1 7, Albert Gough 1 7, Mark T Miedel 1 7, D Lansing Taylor 1 6 7
 
106.New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease
 

Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.

Phillipp Hartmann 1 2, Bernd Schnabl 2 3
 
107.Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
 

Front Endocrinol (Lausanne). 2021 Apr 13;12:663351. doi: 10.3389/fendo.2021.663351.eCollection 2021.

Chance S Friesen 1, Chelsea Hosey-Cojocari 2, Sherwin S Chan 2 3, Iván L Csanaky 2 3 4, Jonathan B Wagner 2 3, Brooke R Sweeney 2 3 5, Alec Friesen 1, Jason D Fraser 2 3, Valentina Shakhnovich 2 3 4 5
 
108.The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease
 

Nutr Rev. 2021 May 9;nuab031. doi: 10.1093/nutrit/nuab031. Online ahead of print.

R Chris Skinner 1, Joel A Hagaman 1
 
109.The Emerging Role of B Cells in the Pathogenesis of NAFLD
 

Hepatology. 2021 May 7. doi: 10.1002/hep.31889. Online ahead of print.

Fanta Barrow 1, Saad Khan 2, Haiguang Wang 1, Xavier S Revelo 1 3
 
110.Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort
 

JHEP Rep. 2021 Mar 2;3(3):100263. doi: 10.1016/j.jhepr.2021.100263. eCollection 2021 Jun.

Carolin V Schneider 1, Inuk Zandvakili 2, Christoph A Thaiss 3 4 5, Kai Markus Schneider 3 4 5
 
111.The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
 

Genes (Basel). 2021 Apr 26;12(5):645. doi: 10.3390/genes12050645.

Emmanuel D Dixon 1, Alexander D Nardo 1, Thierry Claudel 1, Michael Trauner 1
 
112.Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH- the State of the Art
 

Hepatology. 2021 Apr 30. doi: 10.1002/hep.31869. Online ahead of print.

Amreen M Dinani 1, Kris V Kowdley 2, Mazen Noureddin 3
 
113.Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
 

Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978.eCollection 2021.

Leen J M Heyens 1 2 3, Dana Busschots 1 2, Ger H Koek 2 4, Geert Robaeys 1 3 5, Sven Francque 6 7
 
114.Mechanisms and disease consequences of nonalcoholic fatty liver disease
 

Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.

Rohit Loomba 1, Scott L Friedman 2, Gerald I Shulman 3
 
115.Functional characterization of organoids derived from irreversibly damaged NASH patient liver
 

Hepatology. 2021 Apr 26. doi: 10.1002/hep.31857. Online ahead of print.

Sarah McCarron 1, Brooke Bathon 1, Donna M Conlon 1, Deepti Abbey 1, Daniel J Rader 1, Katerina Gawronski 2, Christopher D Brown 2, Kim M Olthoff 3, Abraham Shaked 3, Tobias D Raabe 1
 
116.Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease
 

Front Physiol. 2021 Apr 7;12:656441. doi: 10.3389/fphys.2021.656441.eCollection 2021.

Jordan D Secor 1, Scott C Fligor 1, Savas T Tsikis 1, Lumeng J Yu 1, Mark Puder 1
 
117.Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
 

JHEP Rep. 2021 Feb 19;3(3):100255. doi: 10.1016/j.jhepr.2021.100255. eCollection 2021 Jun.

Arun J Sanyal 1, Lei Ling 2, Ulrich Beuers 3, Alex M DePaoli 2, Hsiao D Lieu 2, Stephen A Harrison 4 5, Gideon M Hirschfield 6
 
118.Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial
 

JHEP Rep. 2021 Feb 17;3(3):100256. doi: 10.1016/j.jhepr.2021.100256. eCollection 2021 Jun.

Magnus Holmer 1 2, Catarina Lindqvist 3 4, Sven Petersson 5 6, John Moshtaghi-Svensson 7, Veronika Tillander 8, Torkel B Brismar 6 9, Hannes Hagström 1 2 10, Per Stål 1 2
 
119.Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease
 

Liver Int. 2021 Apr 25. doi: 10.1111/liv.14899. Online ahead of print.

Sonja Lang 1 2, Anna Martin 1, Xinlian Zhang 3, Fedja Farowski 4 5 6, Hilmar Wisplinghoff 7 8 9, Maria J G T Vehreschild 4 5 6, Marcin Krawczyk 10 11, Angela Nowag 7 9, Anne Kretzschmar 7, Claus Scholz 7, Philipp Kasper 1, Christoph Roderburg 12, Raphael Mohr 13, Frank Lammert 10 14, Frank Tacke 13, Bernd Schnabl 2 15, Tobias Goeser 1, Hans-Michael Steffen 1, Münevver Demir 13
 
120.Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction
 

Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.

Nicholette D Palmer 1, Bratati Kahali 2 3, Annapurna Kuppa 3, Yanhua Chen 3, Xiaomeng Du 3, Mary F Feitosa 4, Lawrence F Bielak 5, Jeffrey R O'Connell 6, Solomon K Musani 7, Xiuqing Guo 8, Albert V Smith 9, Kathleen A Ryan 6, Gudny Eirksdottir 9, Matthew A Allison 10, Donald W Bowden 1, Matthew J Budoff 11, J Jeffrey Carr 12, Yii-Der I Chen 8, Kent D Taylor 8, Adolfo Correa 7, Breland F Crudup 7, Brian Halligan 3, Jian Yang 13, Sharon L R Kardia 5, Lenore J Launer 14, Yi-Ping Fu 15 16, Thomas H Mosley 7, Jill M Norris 17, James G Terry 12, Christopher J O'Donnell 1, Jerome I Rotter 8, Lynne E Wagenknecht 18, Vilmundur Gudnason 9 19, Michael A Province 4, Patricia A Peyser 5, Elizabeth K Speliotes 3
 
121.Definite and indeterminate NASH share similar clinical features and prognosis: a longitudinal study of 1893 biopsy-proven NAFLD subjects
 

Liver Int. 2021 Apr 25. doi: 10.1111/liv.14898. Online ahead of print.

Javier Ampuero 1 2 3, Rocío Aller 4, Rocío Gallego-Durán 2 3, Javier Crespo 5, Javier Abad 6, Águeda González-Rodríguez 7, Judith Gómez-Camarero 8, Joan Caballería 3 9, Oreste Lo Iacono 10, Luis Ibañez 3 11, Javier García-Samaniego 3 12, Rosa Martín-Mateos 3 13, Rubén Francés 3 14, Conrado Fernández-Rodríguez 15, Moisés Diago 16, Germán Soriano 3 17, Raúl J Andrade 3 18, Raquel Latorre 19, Francisco Jorquera 3 20, Rosa María Morillas 3 21, Desamparados Escudero 22, Pamela Estévez 23, Manuel Hernández Guerra 24, Salvador Augustín 25, María Jesús Pareja-Megia 26, Jesús M Banales 3 27, Patricia Aspichueta 28, Salvador Benlloch 3 29, José Miguel Rosales 30, Javier Salmerón 31, Juan Turnes 32, Manuel Romero Gómez 1 2 3, HEPAmet Registry
 
122.Non-alcoholic fatty liver disease
 

Lancet. 2021 Apr 21;S0140-6736(20)32511-3.doi: 10.1016/S0140-6736(20)32511-3. Online ahead of print.

Elizabeth E Powell 1, Vincent Wai-Sun Wong 2, Mary Rinella 3
 
123.Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series
 

Cureus. 2021 Mar 24;13(3):e14082. doi: 10.7759/cureus.14082.

Valentina Rojas Ortiz 1, Jonathan Nieves 2, Enrique C Fernandez 3
 
124.Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
 

Int J Mol Sci. 2021 Apr 17;22(8):4173. doi: 10.3390/ijms22084173.

Miriam Longo 1 2, Erika Paolini 1 3, Marica Meroni 1, Paola Dongiovanni 1
 
125.The importance of glycemic equipoise in NASH
 

Hepatology. 2021 Apr 26. doi: 10.1002/hep.31866. Online ahead of print.

Alina M Allen 1, Brent A Neuschwander-Tetri 2
 
126.Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis
 

J Hepatol. 2021 Apr 19;S0168-8278(21)00248-8. doi: 10.1016/j.jhep.2021.04.013.Online ahead of print.

Geraldine J Ooi 1, Peter J Meikle 2, Kevin Huynh 2, Arul Earnest 3, Stuart K Roberts 4, William Kemp 4, Benjamin L Parker 5, Wendy Brown 1, Paul Burton 6, Matthew J Watt 7
 
127.Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH
 

Hepatol Commun. 2021 Jan 4;5(4):573-588. doi: 10.1002/hep4.1657. eCollection 2021 Apr.

Stephen A Harrison 1 2, Mustafa Bashir 3, Sam E Moussa 4, Kevin McCarty 5, Juan Pablo Frias 6, Rebecca Taub 7, Naim Alkhouri 8

Affiliations expand
 
128.Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
 

Hepatology. 2021 Apr 3. doi: 10.1002/hep.31845. Online ahead of print.

Tracey G Simon 1 2 3, Bjorn Roelstraete 4, Rajani Sharma 5 6, Hamed Khalili 1 2 3, Hannes Hagström 7 8, Jonas F Ludvigsson 4 9 10 11

 
 
129.Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine
 

Front Endocrinol (Lausanne). 2021 Mar 18;12:601160. doi: 10.3389/fendo.2021.601160.eCollection 2021.

Andrea M Mueller 1, Robert Kleemann 2 3, Eveline Gart 2 4, Wim van Duyvenvoorde 2, Lars Verschuren 5, Martien Caspers 5, Aswin Menke 2, Natascha Krömmelbein 1, Kanita Salic 2, Yvonne Burmeister 1, Bernd Seilheimer 1, Martine C Morrison 2 4
 
130.The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)
 

PLoS One. 2021 Apr 6;16(4):e0249614. doi: 10.1371/journal.pone.0249614. eCollection 2021.

Roberta D'Ambrosio 1, Irene Campi 2, Marco Maggioni 3, Riccardo Perbellini 1, Enza Giammona 4, Roberta Stucchi 4, Marta Borghi 1, Elisabetta Degasperi 1, Annalisa De Silvestri 5, Luca Persani 2 6, Laura Fugazzola 2 7, Pietro Lampertico 1 7
 
131.Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction
 

Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.

Nicholette D Palmer 1, Bratati Kahali 2 3, Annapurna Kuppa 3, Yanhua Chen 3, Xiaomeng Du 3, Mary F Feitosa 4, Lawrence F Bielak 5, Jeffrey R O'Connell 6, Solomon K Musani 7, Xiuqing Guo 8, Albert V Smith 9, Kathleen A Ryan 6, Gudny Eirksdottir 9, Matthew A Allison 10, Donald W Bowden 1, Matthew J Budoff 11, J Jeffrey Carr 12, Yii-Der I Chen 8, Kent D Taylor 8, Adolfo Correa 7, Breland F Crudup 7, Brian Halligan 3, Jian Yang 13, Sharon L R Kardia 5, Lenore J Launer 14, Yi-Ping Fu 15 16, Thomas H Mosley 7, Jill M Norris 17, James G Terry 12, Christopher J O'Donnell 1, Jerome I Rotter 8, Lynne E Wagenknecht 18, Vilmundur Gudnason 9 19, Michael A Province 4, Patricia A Peyser 5, Elizabeth K Speliotes 3
 
132.Saroglitazar, a PPAR-a/? Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial
 

Hepatology. 2021 Apr 2. doi: 10.1002/hep.31843. Online ahead of print.

Samer Gawrieh 1, Mazen Noureddin 2, Nicole Loo 3, Rizwana Mohseni 4, Vivek Awasty 5, Kenneth Cusi 6, Kris V Kowdley 7, Michelle Lai 8, Eugene Schiff 9, Deven Parmar 10, Pankaj Patel 11, Naga Chalasani 1
 
133.MAFLD in Obese Children: A Challenging Definition
 

Children (Basel). 2021 Mar 23;8(3):247. doi: 10.3390/children8030247.

Anna Di Sessa 1, Stefano Guarino 1, Giuseppina Rosaria Umano 1, Mattia Arenella 1, Salvatore Alfiero 1, Gaetano Quaranta 1, Emanuele Miraglia Del Giudice 1, Pierluigi Marzuillo 1
 
134.Role of Angiogenesis in the Pathogenesis of NAFLD
 

J Clin Med. 2021 Mar 24;10(7):1338. doi: 10.3390/jcm10071338.

Lin Lei 1, Haquima Ei Mourabit 1, Chantal Housset 1 2, Axelle Cadoret 1, Sara Lemoinne 1 2
 
135.PNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV
 

Biology (Basel). 2021 Mar 21;10(3):242. doi: 10.3390/biology10030242.

Kenneth E Sherman 1, Susan D Rouster 1, Heidi Meeds 1, Javier Tamargo 2, Jun Chen 3, Richard Ehman 3, Marianna Baum 2
 
136.Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults
 

Nutrients. 2021 Mar 17;13(3):966. doi: 10.3390/nu13030966.

Christopher D Crabtree 1, Madison L Kackley 1, Alexandru Buga 1, Brandon Fell 1, Richard A LaFountain 1, Parker N Hyde 1, Teryn N Sapper 1, William J Kraemer 1, Debbie Scandling 2, Orlando P Simonetti 2 3, Jeff S Volek 1
 
137.PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center
 

J Pers Med. 2021 Mar 1;11(3):165. doi: 10.3390/jpm11030165.

Georg Semmler 1 2 3, Lorenz Balcar 1 2, Hannes Oberkofler 4, Stephan Zandanell 1, Michael Strasser 1, David Niederseer 5, Alexandra Feldman 1, Felix Stickel 6, Pavel Strnad 7, Christian Datz 3, Bernhard Paulweber 1, Elmar Aigner 1
 
138.Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study
 

Eat Weight Disord. 2021 Apr 3;1-9. doi: 10.1007/s40519-021-01182-9. Online ahead of print.

Silvia Bettini 1, Roberto Serra 2, Roberto Fabris 2, Chiara Dal Prà 2, Francesca Favaretto 3 2, Francesca Dassie 3, Claudio Duso 3, Roberto Vettor 3 2, Luca Busetto 3 2
 
139.Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort
 

PLoS One. 2021 Apr 1;16(4):e0249491. doi: 10.1371/journal.pone.0249491. eCollection 2021.

Cayden Beyer 1, Chloe Hutton 1, Anneli Andersson 1, Kento Imajo 2, Atsushi Nakajima 2, Dustin Kiker 3, Rajarshi Banerjee 1, Andrea Dennis 1
 
140.The Diabetes Syndrome - A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms
 

Int J Gen Med. 2021 Mar 18;14:923-936. doi: 10.2147/IJGM.S305156. eCollection 2021.

Amy W Rachfal 1, Struan F A Grant 2 3 4, Stanley S Schwartz 5 6
 
141.Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
 

J Exp Pharmacol. 2021 Mar 18;13:329-338. doi: 10.2147/JEP.S265286.eCollection 2021.

Tsipora M Huisman 1, Douglas T Dieterich 1, Scott L Friedman 1
 
142.Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes
 

Front Endocrinol (Lausanne). 2021 Mar 4;12:642432. doi: 10.3389/fendo.2021.642432.eCollection 2021.

Jacqueline Bayliss 1, Geraldine J Ooi 2, William De Nardo 1, Yazmin Johari Halim Shah 2, Magdalene K Montgomery 1, Catriona McLean 3, William Kemp 4, Stuart K Roberts 4, Wendy A Brown 2, Paul R Burton 2, Matthew J Watt 1
 
143.The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population
 

Diabetes Res Clin Pract. 2021 Mar 17;174:108757. doi: 10.1016/j.diabres.2021.108757.Online ahead of print.

Difei Deng 1, Jacob George 2, Dharmintra Pasupathy 3, N Wah Cheung 4
 
144.Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives
 

Curr Obes Rep. 2021 Mar 22. doi: 10.1007/s13679-021-00431-3.Online ahead of print.

Christina-Maria Flessa 1 2, Ioannis Kyrou 2 3 4, Narjes Nasiri-Ansari 1, Gregory Kaltsas 5, Athanasios G Papavassiliou 1, Eva Kassi 6 7, Harpal S Randeva 8 9
 
145.Alternative Etiologies of Liver Disease in Children With Suspected NAFLD
 

Pediatrics. 2021 Mar 30;147(4):e2020009829. doi: 10.1542/peds.2020-009829.Online ahead of print.

Toshifumi Yodoshi 1, Sarah Orkin 1, Ana Catalina Arce-Clachar 1 2, Kristin Bramlage 1, Stavra A Xanthakos 1 2, Pamela L Valentino 3, Marialena Mouzaki 4 2
 
146.LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?
 

Eur J Radiol. 2021 Mar 11;138:109651. doi: 10.1016/j.ejrad.2021.109651. Online ahead of print.

Maxime Barat 1, Thi Thuy Linh Nguyen 2, Clémence Hollande 3, Jean-Baptiste Coty 4, Christine Hoeffel 5, Benoit Terris 6, Anthony Dohan 4, Vincent Mallet 3, Stanislas Pol 3, Philippe Soyer 4
 
147.NASH limits anti-tumour surveillance in immunotherapy-treated HCC
 

Nature. 2021 Mar 24. doi: 10.1038/s41586-021-03362-0. Online ahead of print.

Dominik Pfister 1 2, Nicolás Gonzalo Núñez 3, Roser Pinyol 4, Olivier Govaere 5, Matthias Pinter 6 7, Marta Szydlowska 1, Revant Gupta 8 9, Mengjie Qiu 10, Aleksandra Deczkowska 11, Assaf Weiner 11, Florian Müller 1, Ankit Sinha 12 13, Ekaterina Friebel 3, Thomas Engleitner 14 15 16, Daniela Lenggenhager 17, Anja Moncsek 18, Danijela Heide 1, Kristin Stirm 1, Jan Kosla 1, Eleni Kotsiliti 1, Valentina Leone 1 19, Michael Dudek 20, Suhail Yousuf 10, Donato Inverso 21 22, Indrabahadur Singh 1 23, Ana Teijeiro 24, Florian Castet 4, Carla Montironi 4, Philipp K Haber 25, Dina Tiniakos 5 26, Pierre Bedossa 5, Simon Cockell 27, Ramy Younes 5 28, Michele Vacca 29, Fabio Marra 30, Jörn M Schattenberg 31, Michael Allison 32, Elisabetta Bugianesi 28, Vlad Ratziu 33, Tiziana Pressiani 34, Antonio D'Alessio 34, Nicola Personeni 34 35, Lorenza Rimassa 34 35, Ann K Daly 5, Bernhard Scheiner 6 7, Katharina Pomej 6 7, Martha M Kirstein 36 37, Arndt Vogel 36, Markus Peck-Radosavljevic 38, Florian Hucke 38, Fabian Finkelmeier 39, Oliver Waidmann 39, Jörg Trojan 39, Kornelius Schulze 40, Henning Wege 40, Sandra Koch 41, Arndt Weinmann 41, Marco Bueter 42, Fabian Rössler 42, Alexander Siebenhüner 43, Sara De Dosso 44, Jan-Philipp Mallm 45, Viktor Umansky 46 47, Manfred Jugold 48, Tom Luedde 49, Andrea Schietinger 50 51, Peter Schirmacher 52, Brinda Emu 1, Hellmut G Augustin 21 22, Adrian Billeter 53, Beat Müller-Stich 53, Hiroto Kikuchi 54, Dan G Duda 54, Fabian Kütting 55, Dirk-Thomas Waldschmidt 55, Matthias Philip Ebert 56, Nuh Rahbari 57, Henrik E Mei 58, Axel Ronald Schulz 58, Marc Ringelhan 59 60 61, Nisar Malek 62, Stephan Spahn 62, Michael Bitzer 62, Marina Ruiz de Galarreta 25 63, Amaia Lujambio 25 63 64, Jean-Francois Dufour 65 66, Thomas U Marron 25 67, Ahmed Kaseb 68, Masatoshi Kudo 69, Yi-Hsiang Huang 70 71, Nabil Djouder 24, Katharina Wolter 72 73, Lars Zender 72 73 74, Parice N Marche 75 76, Thomas Decaens 75 76 77, David J Pinato 78 79, Roland Rad 14 15 16, Joachim C Mertens 18, Achim Weber 17 80, Kristian Unger 19, Felix Meissner 12, Susanne Roth 10, Zuzana Macek Jilkova 75 76 78, Manfred Claassen 8 9, Quentin M Anstee 5 81, Ido Amit 11, Percy Knolle 20, Burkhard Becher 3, Josep M Llovet 82 83 84, Mathias Heikenwalder 85

Affiliations collapse
 
148.Bariatric Surgery Reduces Cancer Risk in Adults with Nonalcoholic Fatty Liver Disease and Severe Obesity
 

Gastroenterology. 2021 Mar 17;S0016-5085(21)00529-1. doi: 10.1053/j.gastro.2021.03.021.Online ahead of print.

Vinod K Rustgi 1, You Li 2, Kapil Gupta 2, Carlos D Minacapelli 2, Abhishek Bhurwal 2, Carolyn Catalano 2, Mohamed I Elsaid 2
 
149.The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
 

Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7.

Cyrielle Caussy 1, Adrien Aubin 2, Rohit Loomba 3 4 5
 
150.Sex differences in NAFLD: estrogen influence on the liver-adipose tissue crosstalk
 

Antioxid Redox Signal. 2021 Mar 19. doi: 10.1089/ars.2021.0044. Online ahead of print.

Andrea Morán-Costoya 1 2, Ana María Proenza 1 3 4, Magdalena Gianotti 5 3 6, Isabel Lladó 1 3 7, Adamo Valle 1 3 8
 
151.Ten Thousand Points of Light - Heterogeneity Among the Stars of NASH Fibrosis
 

Hepatology. 2021 Mar 16.doi: 10.1002/hep.31807. Online ahead of print.

James Carter 1, Shuang Wang 1, Scott L Friedman 1
 
152.The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals
 

Expert Rev Gastroenterol Hepatol. 2021 Mar 12. doi: 10.1080/17474124.2021.1902803.Online ahead of print.

David Uihwan Lee 1, Gregory Hongyuan Fan 1, David Jeffrey Hastie 1, Elyse Ann Addonizio 1, Vibhav Narayan Prakasam 1, Ryan Richard Ahern 1, Kristen Jin Seog 1, Raffi Karagozian 1
 
153.Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
 

World J Hepatol. 2021 Feb 27;13(2):233-241. doi: 10.4254/wjh.v13.i2.233.

David Hermanus Wessels 1, Zeil Rosenberg 2
 
154.Coronary artery disease and non-alcoholic fatty liver disease: Clinical correlation using computed tomography coronary calcium scans
 

JGH Open. 2021 Feb 19;5(3):390-395. doi: 10.1002/jgh3.12509. eCollection 2021 Mar.

Richard S Kirby 1, Dina Halegoua-DeMarzio 2
 
155.Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease
 

Hepatology. 2021 Mar 20. doi: 10.1002/hep.31822. Online ahead of print.

Joseph W Beals 1, Gordon I Smith 1, Mahalakshmi Shankaran 2, Anja Fuchs 3, George G Schweitzer 1, Jun Yoshino 1, Tyler Field 2, Marcy Matthews 2, Edna Nyangau 2, Darya Morozov 4, Bettina Mittendorfer 1, Marc K Hellerstein 2, Samuel Klein 1
 
156.European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?
 

JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.

Jeffrey V Lazarus 1, Adam Palayew 2, Patrizia Carrieri 3, Mattias Ekstedt 4, Giulio Marchesini 5, Katja Novak 6, Vlad Ratziu 7, Manuel Romero-Gómez 8, Frank Tacke 9, Shira Zelber-Sagi 10, Helena Cortez-Pinto 11, Quentin M Anstee 12 13
 
157.Treatment candidacy for pharmacologic therapies for NASH
 

Clin Gastroenterol Hepatol. 2021 Mar 9;S1542-3565(21)00228-7.doi: 10.1016/j.cgh.2021.03.005. Online ahead of print.

Ian A Rowe 1, Vincent Wai-Sun Wong 2, Rohit Loomba 3
 
158.The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?
 

Front Nutr. 2021 Feb 16;8:640557. doi: 10.3389/fnut.2021.640557. eCollection 2021.

Theresa Hydes 1 2, Uazman Alam 1 2, Daniel J Cuthbertson 1 2
 
159.Treatments for NAFLD: State of Art
 

Int J Mol Sci. 2021 Feb 26;22(5):2350. doi: 10.3390/ijms22052350.

Alessandro Mantovani 1, Andrea Dalbeni 2
 
160.The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
 

Contemp Clin Trials. 2021 Feb 28;106335. doi: 10.1016/j.cct.2021.106335. Online ahead of print.

Manal F Abdelmalek 1, Edgar D Charles 2, Arun J Sanyal 3, Stephen A Harrison 4, Brent A Neuschwander-Tetri 5, Zachary Goodman 6, Richard A Ehman 7, Morten Karsdal 8, Atsushi Nakajima 9, Shuyan Du 10, Giridhar S Tirucherai 10, George H Klinger 10, Johanna Mora 10, Masayuki Yamaguchi 10, Diane E Shevell 10, Rohit Loomba 11
 
161.Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to help Humans
 

Hepatology. 2021 Feb 26. doi: 10.1002/hep.31777. Online ahead of print.

Mazen Noureddin 1 2 3 4
 
162.Case-finding strategies in non-alcoholic fatty liver disease
 

JHEP Rep. 2020 Dec 5;3(2):100219. doi: 10.1016/j.jhepr.2020.100219.eCollection 2021 Apr.

Jerome Boursier 1 2, Emmanuel A Tsochatzis 3 4
 
163.Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease
 

Frontline Gastroenterol. 2020 Apr 7;12(2):102-107. doi: 10.1136/flgastro-2019-101304.eCollection 2021.

Andrew J Fowell 1, Kirsty Fancey 1, Karen Gamble 1, Kelly Bicknell 2, Joanna K Dowman 1, Paul Howden 3, Richard J Aspinall 1
 
164.Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study
 

BMC Gastroenterol. 2021 Mar 2;21(1):96. doi: 10.1186/s12876-021-01681-0.

Yariv Gerber 1 2 3, Lisa B VanWagner 4, Kristine Yaffe 5, James G Terry 6, Jamal S Rana 7 5, Jared P Reis 8, Stephen Sidney 7
 
165.Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
 

Obes Surg. 2021 Feb 22. doi: 10.1007/s11695-020-04996-1. Online ahead of print.

Saleh A Alqahtani 1 2 3, Pegah Golabi 4 5, James M Paik 4 5, Brian Lam 4, Amir H Moazez 5, Hazem A Elariny 5, Zachary Goodman 4, Zobair M Younossi 6 7
 
166.TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
 

Front Endocrinol (Lausanne). 2021 Jan 29;11:613639.doi: 10.3389/fendo.2020.613639. eCollection 2020.

Christopher R Shepard 1
 
167.Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
 

Front Endocrinol (Lausanne). 2021 Jan 27;11:575843. doi: 10.3389/fendo.2020.575843.eCollection 2020.

Andrea Dennis 1, Matt D Kelly 1, Carolina Fernandes 1, Sofia Mouchti 1, Jonathan A Fallowfield 2, Gideon Hirschfield 3, Michael Pavlides 4 5 6, Stephen Harrison 4 7, Manu V Chakravarthy 8, Rajarshi Banerjee 1, Arun Sanyal 9
 
168.Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions
 

Clin Ther. 2021 Feb 11;S0149-2918(21)00048-5. doi: 10.1016/j.clinthera.2021.01.021.Online ahead of print.

Patrick Campbell 1, Allison Symonds 2, A Sidney Barritt 4th 3
 
169.Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
 

ESC Heart Fail. 2021 Feb 14. doi: 10.1002/ehf2.13250. Online ahead of print.

Anthony E Peters 1, Ambarish Pandey 2, Colby Ayers 2, Kara Wegermann 3, Robert W McGarrah 1, Justin L Grodin 2, Manal F Abdelmalek 3, Tarek Bekfani 4, Vanessa L Blumer 1, Anna Mae Diehl 3, Cynthia A Moylan 3, Marat Fudim 1
 
170.Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
 

Clin Ther. 2021 Feb 10;S0149-2918(21)00016-3. doi: 10.1016/j.clinthera.2021.01.012.Online ahead of print.

Shannon Kogachi 1, Mazen Noureddin 2
 
171.A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
 

J Hepatol. 2021 Feb 10;S0168-8278(21)00099-4. doi: 10.1016/j.jhep.2021.01.047.Online ahead of print.

Stephen A Harrison 1, Mustafa R Bashir 2, Kyoung-Jin Lee 3, Jennifer Shim-Lopez 3, Jonathan Lee 3, Brandee Wagner 3, Nicholas D Smith 3, Hubert C Chen 4, Eric J Lawitz 5
 
172.Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition
 

J Lipid Res. 2020 Dec;61(12):1629-1644. doi: 10.1194/jlr.RA120000924. Epub 2021 Jan 12.

Genta Kakiyama 1, Dalila Marques 2, Rebecca Martin 3, Hajime Takei 4, Daniel Rodriguez-Agudo 2, Sandra A LaSalle 5, Taishi Hashiguchi 6, Xiaoying Liu 7, Richard Green 7, Sandra Erickson 8, Gregorio Gil 9, Michael Fuchs 2, Mitsuyoshi Suzuki 10, Tsuyoshi Murai 11, Hiroshi Nittono 4, Phillip B Hylemon 12, Huiping Zhou 12, William M Pandak 13
 
173.Editorial: Emerging metabolic and transcriptomic signature of PNPLA3 associated NASH
 

Hepatology. 2021 Feb 5. doi: 10.1002/hep.31735. Online ahead of print.

Debanjan Dhar 1, Rohit Loomba 1 2 3
 
174.Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
 

J Clin Med. 2021 Jan 31;10(3):492. doi: 10.3390/jcm10030492.

Amedeo Lonardo 1
 
175.Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease
 

Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724. doi: 10.3238/arztebl.2020.0719.

Yvonne Huber 1, Christian Labenz, Maurice Michel, Marcus-A Wörns, Peter R Galle, Karel Kostev, Jörn M Schattenberg
 
176.Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM
 

BMJ Open Gastroenterol. 2021 Feb;8(1):e000572. doi: 10.1136/bmjgast-2020-000572.

Kelly Lee Hayward 1 2, Amy L Johnson 1 2, Leigh U Horsfall 1 2, Chris Moser 3, Patricia C Valery # 1 4, Elizabeth E Powell # 5 2
 
177.NAFLD-related HCC
 

Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001. Epub 2021 Jan 21.

Bubu A Banini 1, Arun J Sanyal 2
 
178.A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
 

Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750. Online ahead of print.

Amaro Taylor-Weiner 1, Harsha Pokkalla 1, Ling Han 2, Catherine Jia 2, Ryan Huss 2, Chuhan Chung 2, Hunter Elliott 1, Benjamin Glass 1, Kishalve Pethia 1, Oscar Carrasco-Zevallos 1, Chinmay Shukla 1, Urmila Khettry 3, Robert Najarian 4, Ross Taliano 5, G Mani Subramanian 2, Robert P Myers 2, Ilan Wapinski 1, Aditya Khosla 1, Murray Resnick 1 5, Michael C Montalto 1, Quentin M Anstee 6, Vincent Wai-Sun Wong 7, Michael Trauner 8, Eric J Lawitz 9, Stephen A Harrison 10, Takeshi Okanoue 11, Manuel Romero-Gomez 12, Zachary Goodman 13 14, Rohit Loomba 15, Andrew H Beck 1, Zobair M Younossi 13 14
 
179.Human Nonalcoholic Steatohepatitis on a Chip
 

Hepatol Commun. 2020 Nov 29;5(2):217-233. doi: 10.1002/hep4.1647. eCollection 2021 Feb.

May S Freag 1 2, Bumseok Namgung 1 2, Maria E Reyna Fernandez 1 2, Ermanno Gherardi 3, Shiladitya Sengupta 1 2 4, Hae Lin Jang 1
 
180.Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting
 

Hepatol Commun. 2020 Oct 31;5(2):158-167. doi: 10.1002/hep4.1618.eCollection 2021 Feb.

Joana Vieira Barbosa 1 2, Michelle Lai 1
 
181.Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
 

Curr Diab Rep. 2021 Feb 5;21(3):8. doi: 10.1007/s11892-021-01377-5.

Katherine Martin 1 2 3, Anas Hatab 4 5, Varinder S Athwal 4 5 6, Elliot Jokl 4 5, Karen Piper Hanley 7 8
 
182.Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
 

Gut. 2021 Feb 4;gutjnl-2020-322564. doi: 10.1136/gutjnl-2020-322564. Online ahead of print.

Ramy Younes 1 2 3, Olivier Govaere 1, Salvatore Petta 4, Luca Miele 5 6, Dina Tiniakos 1 7, Alastair Burt 1, Ezio David 3, Fabio Maria Vecchio 5 8, Marco Maggioni 9, Daniela Cabibi 10, Duncan McLeod 11, Maria Jesus Pareja 12, Anna Ludovica Fracanzani 13, Rocio Aller 14, Chiara Rosso 3, Javier Ampuero 15, Rocío Gallego-Durán 15, Angelo Armandi 3, Gian Paolo Caviglia 3, Marco Y W Zaki 1 16, Antonio Liguori 5, Paolo Francione 13, Grazia Pennisi 4, Antonio Grieco 5 6, Giovanni Birolo 3, Piero Fariselli 3, Mohammed Eslam 17, Luca Valenti 18, Jacob George 17, Manuel Romero-Gómez 15, Quentin Mark Anstee 19 20, Elisabetta Bugianesi 21
 
183.Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
 

Sci Rep. 2021 Feb 3;11(1):2858. doi: 10.1038/s41598-021-82315-z.

Katharine M Irvine # 1 2, Satomi Okano # 3, Preya J Patel 4 5, Leigh U Horsfall 4 6, Suzanne Williams 7, Anthony Russell 8 9, Elizabeth E Powell 10 11
 
184.Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement
 

Hepatology. 2021 Jan 23. doi: 10.1002/hep.31726. Online ahead of print.

Hannes Hagström 1 2 3, Leon A Adams 4, Alina M Allen 5, Christopher D Byrne 6 7, Yoosoo Chang 8, Henning Grønbaek 9, Mona Ismail 10 11, Peter Jepsen 9, Fasiha Kanwal 12, Jennifer Kramer 12, Jeffrey V Lazarus 13, Michelle T Long 14, Rohit Loomba 15, Philip N Newsome 16 17, Ian A Rowe 18, Seungho Ryu 8 19, Jörn M Schattenberg 20, Marina Serper 21, Nick Sheron 22, Tracey G Simon 23 24, Elliot B Tapper 25, Sarah Wild 26, Vincent Wai-Sun Wong 27, Yusuf Yilmaz 28 29, Shira Zelber-Sagi 30, Fredrik Åberg 31 32
 
185.NAFLD as a metabolic disease in humans: A literature review
 

Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14322. Online ahead of print.

Bertrand Cariou 1, Christopher D Byrne 2, Rohit Loomba 3, Arun J Sanyal 4
 
186.Pathophysiology of NASH in endocrine diseases
 

Endocr Connect. 2021 Jan 1;EC-20-0490.R1. doi: 10.1530/EC-20-0490.Online ahead of print.

Karim Gariani 1, François R Jornayvaz 2
 
187.Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis
 

Hepatol Commun. 2020 Oct 10;5(1):74-82. doi: 10.1002/hep4.1614. eCollection 2021 Jan.

Leah R DeCoste 1, Na Wang 2, Joseph N Palmisano 2, Jean Mendez 3, Udo Hoffmann 4, Emelia J Benjamin 5 6 7, Michelle T Long 3
 
188.Association of liver enzymes with incident diabetes in US Hispanic/Latino adults
 

Diabet Med. 2021 Jan 12;e14522. doi: 10.1111/dme.14522. Online ahead of print.

Simin Hua 1, Qibin Qi 1, Jorge R Kizer 2, Jessica Williams-Nguyen 3, Howard D Strickler 1, Bharat Thyagarajan 4, Martha Daviglus 5, Gregory A Talavera 6, Neil Schneiderman 7, Scott J Cotler 8, Jianwen Cai 9, Robert Kaplan 1 3, Carmen R Isasi 1
 
189.Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease
 

Diagnostics (Basel). 2021 Jan 9;11(1):E98. doi: 10.3390/diagnostics11010098.

Stefano Ballestri 1, Alessandro Mantovani 2, Enrica Baldelli 3, Simonetta Lugari 4, Mauro Maurantonio 4, Fabio Nascimbeni 4, Alessandra Marrazzo 1, Dante Romagnoli 5, Giovanni Targher 2, Amedeo Lonardo 6
 
190.Liver Fat Quantification by Ultrasound in Children: A Prospective Study
 

AJR Am J Roentgenol. 2021 Jan 13. doi: 10.2214/AJR.20.24874. Online ahead of print.

Aurélie D'Hondt 1, Erika Rubesova 1, Hua Xie 2, Vijay Shamdasani 3, Richard A Barth 1
 
191.Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
 

World J Hepatol. 2020 Dec 27;12(12):1168-1181. doi: 10.4254/wjh.v12.i12.1168

Madeleine G Gill 1, Avik Majumdar 1
 
192.Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping
 

J Med Internet Res. 2021 Jan 15;23(1):e20491. doi: 10.2196/20491.

Kate Hallsworth 1 2 3, Stuart McPherson 1 2 3, Quentin M Anstee 1 2 3, Darren Flynn 4, Laura Haigh 1 2 3, Leah Avery 3 4
 
193.Ceramide Salvage, Gut Mucosal IgA Signaling, and Diet-Induced NASH
 

Hepatology. 2021 Jan 15. doi: 10.1002/hep.31707. Online ahead of print.

Scott A McHenry 1, Nicholas O Davidson 1
 
194.Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease
 

Transl Gastroenterol Hepatol. 2021 Jan 5;6:3. doi: 10.21037/tgh.2020.02.18.eCollection 2021.

Eric K Kwong 1, Puneet Puri 2 3
 
195.Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry
 

Transl Gastroenterol Hepatol. 2021 Jan 5;6:5. doi: 10.21037/tgh.2020.01.04.eCollection 2021.

Amon Asgharpour 1, Amreen Dinani 1, Scott L Friedman 1
 
196.Maternal Diet Alters Trained Immunity in the Pathogenesis of Pediatric NAFLD
 

J Cell Immunol. 2020;2(6):315-325. doi: 10.33696/immunology.2.061.

Karen R Jonscher 1 2, Jesse Abrams 2, Jacob E Friedman 2 3
 
197.Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine
 

J Med Syst. 2021 Jan 11;45(2):22. doi: 10.1007/s10916-020-01693-5.

Orit Goldman 1, Ofir Ben-Assuli 2, Ori Rogowski 3, David Zeltser 3, Itzhak Shapira 3, Shlomo Berliner 3, Shira Zelber-Sagi 4 5, Shani Shenhar-Tsarfaty 3
 
198.Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis
 

Obes Surg. 2021 Jan 6. doi: 10.1007/s11695-020-05084-0. Online ahead of print.

Saurabh Chandan 1, Babu P Mohan 2, Shahab R Khan 3, Antonio Facciorusso 4, Daryl Ramai 5, Lena L Kassab 6, Neil Bhogal 7, Ravishankar Asokkumar 8, Gortrand Lopez-Nava 8, Stephanie McDonough 2, Douglas G Adler 9
 
199.Dietary approaches to managing nonalcoholic fatty liver disease
 

Nurse Pract. 2020 Dec 31;Publish Ahead of Print. doi: 10.1097/01.NPR.0000731560.23509.ff.Online ahead of print.

Dalia El Khoury 1, Rosemary J Pauley, Carol Lynn Berseth
 
200.Lean NAFLD: an underrecognized and challenging disorder in medicine
 

Rev Endocr Metab Disord. 2021 Jan 3. doi: 10.1007/s11154-020-09621-1.Online ahead of print.

Sheila Maier 1, Amanda Wieland 2, Melanie Cree-Green 3, Kristen Nadeau 3, Shelby Sullivan 4, Miguel A Lanaspa 5, Richard J Johnson 5, Thomas Jensen 6 7
 
201.Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
 

World J Hepatol. 2020 Nov 27;12(11):993-1003. doi: 10.4254/wjh.v12.i11.993.

Catherine J Choi 1, Stanley H Weiss 2, Umair M Nasir 1, Nikolaos T Pyrsopoulos 3
 
202.Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease
 

Mol Metab. 2020 Dec 22;101154. doi: 10.1016/j.molmet.2020.101154. Online ahead of print.

Chris E Shannon 1, Mukundan Ragavan 2, Juan Pablo Palavicini 3, Marcel Fourcaudot 1, Terry Bakewell 1, Ivan A Valdez 1, Iriscilla Ayala 1, Eunsook S Jin 4, Muniswamy Madesh 5, Xianlin Han 6, Matthew E Merritt 2, Luke Norton 7
 
203.Glycogenosis is Common in Nonalcoholic Fatty Liver Disease and is Independently Associated with Ballooning, but Lower Steatosis and Lower Fibrosis
 

Liver Int. 2020 Dec 22. doi: 10.1111/liv.14773. Online ahead of print.

Daniela S Allende 1, Samer Gawrieh 2, Oscar W Cummings 3, Patricia Belt 4, Laura Wilson 4, Mark Van Natta 4, Cynthia A Behling 5, Danielle Carpenter 6, Ryan M Gill 7, David E Kleiner 8, Mathew M Yeh 9, Naga Chalasani 2, Cynthia D Guy 10, NASH Clinical Research Network
 
204.Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steato-hepatitis: a hierarchical network meta-analysis
 

Diabetes Obes Metab. 2020 Dec 23. doi: 10.1111/dom.14304. Online ahead of print.

Simona Panunzi 1, Sabina Maltese 2, Ornella Verrastro 3 4, Luca Labbate 2, Andrea De Gaetano 1, Maurizio Pompili 3 4, Esmeralda Capristo 3 4, Stefan R Bornstein 5 6, Geltrude Mingrone 3 4 6
 
205.FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
 

Front Endocrinol (Lausanne). 2020 Dec 14;11:601290.doi: 10.3389/fendo.2020.601290. eCollection 2020.

Erik J Tillman 1, Tim Rolph 1
 
206.Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
 

Patient. 2020 Dec 18. doi: 10.1007/s40271-020-00485-w. Online ahead of print.

Lynda C Doward 1, Maria-Magdalena Balp 2, James Twiss 3, Christina Slota 4, Donna Cryer 5, Clifford A Brass 6, Quentin M Anstee 7 8, Arun J Sanyal 9
 
207.Metabolic drivers of non-alcoholic fatty liver disease
 

Mol Metab. 2020 Dec 17;101143. doi: 10.1016/j.molmet.2020.101143. Online ahead of print.

Kendra K Bence 1, Morris J Birnbaum 2
 
208.Incidence of Depression and Anxiety in a Cohort of Adolescents with Nonalcoholic Fatty Liver Disease
 

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003024. Online ahead of print.

Sheila Noon 1, Danielle D'Annibale, Melanie Schwimmer, Jacqueline Shiels, Jennifer Arin, Janis Durelle, Kimberly Newton, Nidhi Goyal, Jeffrey Schwimmer
 
209.Evaluation of Non-Alcoholic Fatty Liver Disease in Pediatric Patients with Inflammatory Bowel Disease
 

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003023. Online ahead of print.

Mallory E Cohen 1, Parakkal Deepak, Geetika Khanna, Charles M Samson
 
210.Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis
 

World J Gastroenterol. 2020 Dec 14;26(46):7367-7381. doi: 10.3748/wjg.v26.i46.7367.

Peter Hoffmann 1, Victoria Jung 2, Rouven Behnisch 3, Annika Gauss 2
 
211.Non-alcoholic fatty liver disease - a special consideration in TIPS?
 

Liver Transpl. 2020 Dec 21. doi: 10.1002/lt.25976. Online ahead of print.

Sarah Wang 1, Juan G Abraldes 1
 
212.A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies
 

Mod Pathol. 2020 Dec 9. doi: 10.1038/s41379-020-00718-1. Online ahead of print.

Joshua J Levy 1 2 3, Nasim Azizgolshani 4, Michael J Andersen Jr 5, Arief Suriawinata 5, Xiaoying Liu 5, Mikhail Lisovsky 5, Bing Ren 5, Carly A Bobak 6 7 8 9, Brock C Christensen 4 10 11, Louis J Vaickus 5
 
213.Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease
 

Cell Metab. 2020 Dec 3;S1550-4131(20)30605-7. doi: 10.1016/j.cmet.2020.11.010.Online ahead of print.

S R Sharpton 1, B Schnabl 2, R Knight 3, R Loomba 4
 
214.NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
 

Diabetes Metab. 2020 Dec 6;101215. doi: 10.1016/j.diabet.2020.101215.Online ahead of print.

Giovanni Targher 1, Kathleen E Corey 2, Christopher D Byrne 3a
 
215. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
 

Clin Mol Hepatol. 2020 Dec 10. doi: 10.3350/cmh.2020.0129. Online ahead of print.

Erica Jennison 1, Christopher D Byrne 2 3
 
216.Emerging Therapies for the Treatment of Non-Alcoholic Steatohepatitis: A Systematic Review
 

Pharmacotherapy. 2020 Dec 5. doi: 10.1002/phar.2489. Online ahead of print.

Erenie Guirguis 1, Yasmin Grace 1, Anthony Bolson 1, Matthew J DellaVecchia 1, Melissa Ruble 2
 
217.Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis
 

Liver Int. 2020 Dec 7. doi: 10.1111/liv.14749. Online ahead of print.

Anna Roskilly 1, Amy Hicks 1, Eleanor J Taylor 1, Rebecca Jones 1, Richard Parker 1, Ian A Rowe 1 2
 
218.Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations
 

Am J Gastroenterol. 2020 Dec 7. doi: 10.14309/ajg.0000000000001054. Online ahead of print.

Zobair M Younossi 1, Mazen Noureddin 2, David Bernstein 3, Paul Kwo 4, Mark Russo 5, Mitchell L Shiffman 6, Ziad Younes 7, Manal Abdelmalek 8
 
219.Regulation of gene transcription by thyroid hormone receptor ß agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)
 

PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. eCollection 2020.

Xuan G Luong 1, Sarah K Stevens 1, Andreas Jekle 1, Tse-I Lin 2, Kusum Gupta 1, Dinah Misner 1, Sushmita Chanda 1, Sucheta Mukherjee 1, Caroline Williams 1, Antitsa Stoycheva 1, Lawrence M Blatt 1, Leonid N Beigelman 1, Julian A Symons 1, Pierre Raboisson 2, David McGowan 2, Koen Vandyck 2, Jerome Deval 1
 
220.The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)
 

Gastroenterology. 2020 Dec 8;S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.Online ahead of print.

Zobair M Younossi 1, Quentin M Anstee 2, Vincent Wai-Sun Wong 3, Michael Trauner 4, Eric J Lawitz 5, Stephen A Harrison 6, Marianne Camargo 7, Kathryn Kersey 7, G Mani Subramanian 7, Robert P Myers 7, Maria Stepanova 8
 
221.Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression
 

Metabolism. 2020 Dec 1;154457. doi: 10.1016/j.metabol.2020.154457. Online ahead of print.

Nisreen Nimer 1, Ibrahim Choucair 2, Zeneng Wang 2, Ina Nemet 2, Lin Li 2, Janet Gukasyan 3, Taylor L Weeks 2, Naim Alkhouri 4, Nizar Zein 5, W H Wilson Tang 6, Michael A Fischbach 5, J Mark Brown 2, Hooman Allayee 3, Srinivasan Dasarathy 7, Valentin Gogonea 8, Stanley L Hazen 9
 
222.Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis
 

Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660. Online ahead of print.

Tracey G Simon 1 2 3, Andrew T Chan 1 2 3 4 5 6, Curtis Huttenhower 5 6 7
 
223.Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
 

Curr Hypertens Rev. 2020 Dec 9. doi: 10.2174/1573402116999201209203534.Online ahead of print.

Eddison Godinez-Leiva 1, Fernando Bril 2
 
224.The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017
 

Hepatol Commun. 2020 Sep 14;4(12):1769-1780. doi: 10.1002/hep4.1599. eCollection 2020 Dec.

James M Paik 1, Pegah Golabi 1, Youssef Younossi 2, Manirath Srishord 1, Alita Mishra 3, Zobair M Younossi 1 3
 
225.AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Expert Review
 

Gastroenterology. 2020 Dec 8;S0016-5085(20)35538-4.doi: 10.1053/j.gastro.2020.11.051. Online ahead of print.

Zobair M Younossi 1, Kathleen E Corey 2, Joseph K Lim 3
 
226.Epidemiology and natural history of non-alcoholic fatty liver disease
 

Metabolism. 2016 Aug;65(8):1017-25. doi: 10.1016/j.metabol.2016.01.012.Epub 2016 Jan 29.

Yousef Fazel 1, Aaron B Koenig 1, Mehmet Sayiner 1, Zachary D Goodman 2, Zobair M Younossi 3
 
227.Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma
 

Transplantation. 2018 Apr;102(4):640-647.doi: 10.1097/TP.0000000000002043.

Erin M Sadler 1 2, Neil Mehta 3, Mamatha Bhat 1 4, Anand Ghanekar 1 2, Paul D Greig 1 2, David R Grant 1 2, Francis Yao 3, Gonzalo Sapisochin 1 2
 
228.A diabetologist
 

Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

Kenneth Cusi 1 2
 
229.Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?
 

Gut. 2002 May;50(5):585-8.doi: 10.1136/gut.50.5.585.

C P Day 1
 
230.Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
 

Medicine (Baltimore). 2018 Aug;97(31):e11518.doi: 10.1097/MD.0000000000011518.

Pegah Golabi 1, Haley Bush 1, Maria Stepanova 2, Cameron T Locklear 3, Ira M Jacobson 4, Alita Mishra 3, Gregory Trimble 3, Madeline Erario 3, Chapy Venkatesan 3, Issah Younossi 2, Zachary Goodman 1 3, Zobair M Younossi 1 3
 
231.Practice patterns in NAFLD and NASH: real life differs from published guidelines
 

Therap Adv Gastroenterol. 2016 Jan;9(1):4-12. doi: 10.1177/1756283X15611581.

Mary E Rinella 1, Zurabi Lominadze 2, Rohit Loomba 3, Michael Charlton 4, Brent A Neuschwander-Tetri 5, Stephen H Caldwell 6, Kris Kowdley 7, Stephen A Harrison 8
 
232.Transient Versus 2-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD
 

Hepatology. 2020 Nov 24. doi: 10.1002/hep.31655. Online ahead of print.

Christophe Cassinotto 1 2, Jérome Boursier 3 4, Anita Paisant 5, Boris Guiu 1, Marie Irles-Depe 6, Clémence Canivet 3 4, Christophe Aube 4 5, Victor de Ledinghen 6
 
233.Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
 

Front Endocrinol (Lausanne). 2020 Oct 21;11:592157.doi: 10.3389/fendo.2020.592157. eCollection 2020.

Kavita Jadhav 1, Taylor S Cohen 1
 
234.Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management
 

Am Fam Physician. 2020 Nov 15;102(10):603-612.

Erin Westfall 1, Robert Jeske 1, Andrew R Bader 2
 
235.GPCRs get Fatty: The Role of G Protein-Coupled Receptor Signaling in the Development and Progression of Nonalcoholic Fatty Liver Disease
 

Am J Physiol Gastrointest Liver Physiol. 2020 Nov 18. doi: 10.1152/ajpgi.00275.2020.Online ahead of print.

Ryan Kurtz 1, Meghan F Anderman 1, Blythe D Shepard 1
 
236.NAFLD and COVID-19: a Pooled Analysis
 

SN Compr Clin Med. 2020 Nov 6;1-4. doi: 10.1007/s42399-020-00631-3. Online ahead of print.

Sonali Sachdeva 1, Harshwardhan Khandait 2, Jonathan Kopel 3, Mark M Aloysius 4, Rupak Desai 5, Hemant Goyal 4
 
237.Genetic and epigenetic factors determining NAFLD risk
 

Mol Metab. 2020 Nov 4;101111. doi: 10.1016/j.molmet.2020.101111. Online ahead of print.

Wenke Jonas 1, Annette Schürmann 2
 
238.Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes
 

Hepatol Commun. 2020 Aug 28;4(11):1637-1650. doi: 10.1002/hep4.1581. eCollection 2020 Nov.

Zobair M Younossi 1 2, Vincent Wai-Sun Wong 3, Quentin M Anstee 4 5, Manuel Romero-Gomez 6, Michael H Trauner 7, Stephen A Harrison 8, Eric J Lawitz 9, Takeshi Okanoue 10, Marianne Camargo 11, Kathryn Kersey 11, Robert P Myers 11, Zachary Goodman 1 2, Maria Stepanova 12
 
239.Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH
 

Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622. Online ahead of print.

Rohit Loomba 1, Mazen Noureddin 2, Kris V Kowdley 3, Anita Kohli 4, Aasim Sheikh 5, Guy Neff 6, Bal Raj Bhandari 7, Nadege Gunn 8, Stephen H Caldwell 9, Zachary Goodman 10, Ilan Wapinski 11, Murray Resnick 11, Andrew H Beck 11, Dora Ding 12, Catherine Jia 12, Jen-Chieh Chuang 12, Ryan S Huss 12, Chuhan Chung 12, G Mani Subramanian 12, Robert P Myers 12, Keyur Patel 13, Brian B Borg 14, Reem Ghalib 15, Heidi Kabler 16, John Poulos 17, Ziad Younes 18, Magdy Elkhashab 19, Tarek Hassanein 20, Rajalakshmi Iyer 21, Peter Ruane 22, Mitchell L Shiffman 23, Simone Strasser 24, Vincent Wai-Sun Wong 25, Naim Alkhouri 26, ATLAS Investigators
 
240.MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis
 

Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624. Online ahead of print.

Rohit Loomba 1 2
 
241.A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
 

N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395. Online ahead of print.

Philip N Newsome 1, Kristine Buchholtz 1, Kenneth Cusi 1, Martin Linder 1, Takeshi Okanoue 1, Vlad Ratziu 1, Arun J Sanyal 1, Anne-Sophie Sejling 1, Stephen A Harrison 1, NN9931-4296 Investigators
 
242.Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT
 

BMC Gastroenterol. 2020 Oct 31;20(1):362. doi: 10.1186/s12876-020-01492-9.

Heather Patton 1 2, Raoul Burchette 3, Stephanie Tovar 3, Jose Pio 3, Jiaxiao Shi 3, Lisa M Nyberg 4 3
 
243.Relationship of IGF-1 and IGF Binding Proteins to Disease Severity and Glycemia in Non-Alcoholic Fatty Liver Disease
 

J Clin Endocrinol Metab. 2020 Oct 30;dgaa792. doi: 10.1210/clinem/dgaa792.Online ahead of print.

Takara L Stanley 1, Lindsay T Fourman 1, Isabel Zheng 1, Colin M McClure 1, Meghan N Feldpausch 1, Martin Torriani 2, Kathleen E Corey 3, Raymond T Chung 3, Hang Lee 4, David E Kleiner 5, Colleen M Hadigan 6, Steven K Grinspoon 1
 
244.NASH: Connecting the dots with patients in mind
 

Endocrinol Diabetes Metab. 2020 Oct 21;3(4):e00109. doi: 10.1002/edm2.109.eCollection 2020 Oct.

Donna R Cryer 1
 
245.Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
 

Endocrinol Diabetes Metab. 2019 Dec 10;3(4):e00105. doi: 10.1002/edm2.105.eCollection 2020 Oct.

Mazen Noureddin 1, Mark D Muthiah 2 3, Arun J Sanyal 4
 
246.Determinants of Physical Activity Engagement in Patients With Nonalcoholic Fatty Liver Disease: The Need for an Individualized Approach to Lifestyle Interventions
 

Phys Ther. 2020 Oct 26;pzaa195. doi: 10.1093/ptj/pzaa195. Online ahead of print.

Philip O'Gorman 1, Ann Monaghan 1, Marie McGrath 2, Sara Naimimohasses 2 3, John Gormley 1, Suzanne Norris 2 3
 
247.Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors
 

PLoS One. 2020 Oct 27;15(10):e0241357. doi: 10.1371/journal.pone.0241357. eCollection 2020.

Jake P Mann 1 2 3, Paul Carter 3 4, Matthew J Armstrong 5, Hesham K Abdelaziz 6 7, Hardeep Uppal 3, Billal Patel 6, Suresh Chandran 8, Ranjit More 6, Philip N Newsome 9 10, Rahul Potluri 3
 
248.Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination
 

Sci Rep. 2020 Oct 27;10(1):18345. doi: 10.1038/s41598-020-75227-x.

Valentin Blank 1 2, David Petroff 2 3, Sebastian Beer 1, Albrecht Böhlig 4, Maria Heni 1, Thomas Berg 4, Yvonne Bausback 5, Arne Dietrich 2 6, Anke Tönjes 7, Marcus Hollenbach 1, Matthias Blüher 2 7, Volker Keim 1, Johannes Wiegand 4, Thomas Karlas 8
 
249.Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice
 

Hepatology. 2020 Oct 27. doi: 10.1002/hep.31599. Online ahead of print.

Elizabeth M Brunt 1, David E Kleiner 2, Danielle H Carpenter 3, Mary Rinella 4, Stephen A Harrison 5, Rohit Loomba 6, Zobair Younossi 7, Brent A Neuschwander-Tetri 8, Arun J Sanyal 9, American Association for the Study of Liver Diseases NASH Task Force
 
250.Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals
 

Frontline Gastroenterol. 2019 Dec 13;11(6):478-483.doi: 10.1136/flgastro-2018-101119. eCollection 2020 Oct.

Meaghan Phipps 1, Julia Wattacheril 2
 
251.Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chronic liver disease: effect of level of training and experience
 

Abdom Radiol (NY). 2020 Sep 9. doi: 10.1007/s00261-020-02719-9. Online ahead of print.

Roberto Cannella 1 2, Navya Dasyam 3, Su-Hun Seo 4, Alessandro Furlan 3, Amir A Borhani 3 5
 
252.Lipoprotein and Metabolic Profiles Indicate Similar Cardiovascular Risk of Liver Steatosis and NASH
 

Digestion. 2020 Oct 20;1-11. doi: 10.1159/000510600. Online ahead of print.

Aline Gottlieb 1 2, Anna-Sophia Leven 3, Jan-Peter Sowa 2 4, Katrin Borucki 5, Alexander Link 2, Elvan Yilmaz 6, Sitke Aygen 6, Ali Canbay 7, Mustafa Porsch-Özcürümez 4
 
253.Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease
 

Transl Gastroenterol Hepatol. 2020 Oct 5;5:49. doi: 10.21037/tgh.2019.12.05.eCollection 2020.

Kyle E Robinson 1, Vijay H Shah 1
 
254.Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling
 

Front Endocrinol (Lausanne). 2020 Sep 18;11:572490.doi: 10.3389/fendo.2020.572490. eCollection 2020.

Sara Della Torre 1
 
255.What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
 

Metabolites. 2020 Oct 8;10(10):E397. doi: 10.3390/metabo10100397.

Giovanni Targher 1
 
256.Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms
 

Nutrients. 2020 Oct 16;12(10):E3166. doi: 10.3390/nu12103166.

Ashok Mandala 1, Rachel C Janssen 1, Sirish Palle 2, Kevin R Short 1 3 4, Jacob E Friedman 1 3 4
 
257.Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV
 

Clin Gastroenterol Hepatol. 2020 Oct 15;S1542-3565(20)31431-2.doi: 10.1016/j.cgh.2020.10.018. Online ahead of print.

Jordan E Lake 1, Turner Overton 2, Susanna Naggie 3, Mark Sulkowski 4, Rohit Loomba 5, David E Kleiner 6, Jennifer C Price 7, Kara W Chew 8, Raymond T Chung 9, Kathleen E Corey 10
 
258.Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
 

Contemp Clin Trials. 2020 Oct 8;106174. doi: 10.1016/j.cct.2020.106174. Online ahead of print.

Stephen A Harrison 1, Salvatore Calanna 2, Kenneth Cusi 3, Martin Linder 4, Takeshi Okanoue 5, Vlad Ratziu 6, Arun Sanyal 7, Anne-Sophie Sejling 8, Philip N Newsome 9
 
259.Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
 

J Hepatol. 2020 Oct 7;S0168-8278(20)33673-4. doi: 10.1016/j.jhep.2020.09.029.Online ahead of print.

Catherine Frenette 1, Zeid Kayali 2, Edward Mena 3, Parvez S Mantry 4, Kathryn J Lucas 5, Guy Neff 6, Miguel Rodriguez 7, Paul J Thuluvath 8, Ethan Weinberg 9, Bal R Bhandari 10, James Robinson 11, Nicole Wedick 12, Jean L Chan 11, David T Hagerty 11, Kris V Kowdley 13, IDN-6556-17 Study Investigators
 
260.One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
 

J Clin Med. 2020 Oct 6;9(10):E3213. doi: 10.3390/jcm9103213.

Louise Vedtofte 1 2, Emilie Bahne 1 2, Signe Foghsgaard 1 2 3, Jonatan I Bagger 1 2, Camilla Andreasen 1 2, Charlotte Strandberg 4, Peter M Gørtz 5, Jens J Holst 6 7, Henning Grønbæk 8, Jens A Svare 9, Tine D Clausen 10, Elisabeth R Mathiesen 11 12, Peter Damm 12 13, Lise L Gluud 12 14, Filip K Knop 1 2 7 12, Tina Vilsbøll 1 2 12
 
261.The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
 

Contemp Clin Trials. 2020 Oct 9;106175. doi: 10.1016/j.cct.2020.106175. Online ahead of print.

Timothy Hardy 1, Kristy Wonders 2, Ramy Younes 3, Guruprasad P Aithal 4, Rocio Aller 5, Michael Allison 6, Pierre Bedossa 2, Fay Betsou 7, Jerome Boursier 8, M Julia Brosnan 9, Alastair Burt 1, Jeremy Cobbold 10, Helena Cortez-Pinto 11, Chris P Day 1, Jean-Francois Dufour 12, Mattias Ekstedt 13, Sven Francque 14, Stephen Harrison 15, Luca Miele 16, Patrik Nasr 13, George Papatheodoridis 17, Salvatore Petta 18, Dina Tiniakos 19, Richard Torstenson 20, Luca Valenti 21, Adriaan G Holleboom 22, Hannele Yki-Jarvinen 23, Andreas Geier 24, Manuel Romero-Gomez 25, Vlad Ratziu 26, Elisabetta Bugianesi 27, Jörn M Schattenberg 28, Quentin M Anstee 29, LITMUS Consortium
 
262.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
 

Gut. 2020 Oct 9;gutjnl-2020-322786. doi: 10.1136/gutjnl-2020-322786. Online ahead of print.

Tracey G Simon 1 2 3, Bjorn Roelstraete 4, Hamed Khalili 1 2 3, Hannes Hagström 5, Jonas F Ludvigsson 6 7 8 9 10
 
263.Testosterone is Associated With Nonalcoholic Steatohepatitis (NASH) and Fibrosis in Pre-Menopausal Women With NAFLD
 

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31375-6.doi: 10.1016/j.cgh.2020.09.045. Online ahead of print.

Monika Sarkar 1, Ayako Suzuki 2, Manal Abdelmalek 2, Katherine Yates 3, Laura Wilson 3, Nathan M Bass 4, Ryan Gill 2, Marcelle Cedars 5, Norah Terrault 6, NASH Clinical Research Network (NASH CRN)
 
264.Non-Alcoholic Fatty Liver Disease in a sample of individuals with Bipolar Disorders: Results From the FACE-BD Cohort
 

Acta Psychiatr Scand. 2020 Oct 4. doi: 10.1111/acps.13239. Online ahead of print.

Ophelia Godin 1 2, Marion Leboyer 1 2, Raoul Belzeaux 1 3, Frank Bellivier 1 4, Joséphine Loftus 1 5, Philippe Courtet 1 6, Caroline Dubertret 1 7, Sebastien Gard 1 8, Chantal Henry 9, Pierre-Michel Llorca 1 10, Raymund Schwan 1 11, Christine Passerieux 1 12, Mircea Polosan 1 13, Ludovic Samalin 1 10, Emilie Olié 1 6, Bruno Etain 1 4, FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators

 

Collaborators

  • FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators: 

B Etain, C Henry, E Olié, M Leboyer, E Haffen, P M Llorca, V Barteau, S Bensalem, O Godin, H Laouamri, K Souryis, H Mondor, S Hotier, A Pelletier, N Drancourt, J P Sanchez, E Saliou, C Hebbache, J Petrucci, L Willaume, E Bourdin, F Bellivier, M Carminati, B Etain, J Maruani, E Marlinge, M Meyrel, B Antoniol, A Desage, S Gard, A Jutant, K Mbailara, I Minois, L Zanouy, L Bardin, A Cazals, P Courtet, B Deffinis, D Ducasse, M Gachet, A Henrion, F Molière, B Noisette, E Olié, G Tarquini, R Belzeaux, N Correard, F Groppi, A Lefrere, L Lescalier, E Moreau, J Pastol, M Rebattu, B Roux, N Viglianese, R Cohen, Raymund Schwan, J P Kahn, M Milazzo, O Wajsbrot-Elgrabli, T Bougerol, B Fredembach, A Suisse, B Halili, A Pouchon, M Polosan, A M Galliot, I Grévin, A S Cannavo, N Kayser, C Passerieux, P Roux, V Aubin, I Cussac, M A Dupont, J Loftus, I Medecin, C Dubertret, N Mazer, C Portalier, C Scognamiglio, A Bing
 
265.Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
 

Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.

Jeffrey Budd 1, Kenneth Cusi 2 3
 
266.Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease
 

Aliment Pharmacol Ther. 2020 Oct;52(7):1185-1194. doi: 10.1111/apt.16016. Epub 2020 Aug 17.

Ali Canbay 1, Nandita Kachru 2, Jennifer Scarlet Haas 3, Jan-Peter Sowa 1, Dominic Meise 3, Ahmet Burak Ozbay 2
 
267.Identifying High-Risk NASH Patients: What We Know so Far
 

Hepat Med. 2020 Aug 21;12:125-138. doi: 10.2147/HMER.S265473.eCollection 2020.

Marten Schulz 1, Frank Tacke 1
 
268.Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease
 

BMJ Open. 2020 Sep 28;10(9):e040970. doi: 10.1136/bmjopen-2020-040970.

Theresa Hydes 1, Ryan Buchanan 2, Oliver J Kennedy 2, Simon Fraser 2, Julie Parkes 2, Paul Roderick 2
 
269.Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival
 

Public Health. 2020 Sep 26;187:165-171. doi: 10.1016/j.puhe.2020.07.017. Online ahead of print.

H Innes 1, J R Morling 2, E A Aspinall 3, D J Goldberg 3, S J Hutchinson 3, I N Guha 4
 
270.Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data
 

Adv Ther. 2020 Oct 1.doi: 10.1007/s12325-020-01503-x. Online ahead of print.

Grit Andersen 1, Leona Plum-Mörschel 2, Paul D Hockings 3 4, Anni Morsing 5, Mads S Palle 6, Olivia Svolgaard 5, Anne Flint 7
 
271.The pharmacological treatment of non-alcoholic fatty liver disease in children
 

Expert Rev Clin Pharmacol. 2020 Sep 26. doi: 10.1080/17512433.2020.1829468.Online ahead of print.

Annalisa Crudele 1, Nadia Panera 1, Maria Rita Braghini 1, Clara Balsano 2, Anna Alisi 1
 
272.Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation and Death in NAFLD
 

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31374-4.doi:10.1016/j.cgh.2020.09.044. Online ahead of print.

Tolga Gidener 1, Omar T Ahmed 1, Joseph J Larson 2, Kristin C Mara 2, Terry M Therneau 2, Sudhakar K Venkatesh 3, Richard L Ehman 3, Meng Yin 3, Alina M Allen 4
 
273.The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care
 

JHEP Rep. 2020 Aug 4;2(6):100168. doi: 10.1016/j.jhepr.2020.100168. eCollection 2020 Dec.

Wolf Peter Hofmann 1 2, Peter Buggisch 2 3, Lisa Schubert 1 4, Nektarios Dikopoulos 5, Jeannette Schwenzer 6, Marion Muche 4, Gisela Felten 7, Renate Heyne 8, Patrick Ingiliz 9, Anna Schmidt 10, Kerstin Stein 11, Heiner Wedemeyer 12, Thomas Berg 13, Johannes Wiegand 13, Frank Lammert 14, Stefan Zeuzem 15, Jörn M Schattenberg 16 17
 
274.A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis
 

Sci Rep. 2020 Sep 17;10(1):15308. doi: 10.1038/s41598-020-71995-8.

Andrea Dennis 1, Sofia Mouchti 2, Matt Kelly 2, Jonathan A Fallowfield 3, Gideon Hirschfield 4, Michael Pavlides 5, Rajarshi Banerjee 2
 
275.Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease
 

J Clin Hypertens (Greenwich). 2020 Sep 17. doi: 10.1111/jch.13938. Online ahead of print.

Jillian Price 1, Carey Escheik 1 2, Ali Weinstein 3, Patrice Winter 1 2, Lynn Gerber 1, Zobair Younossi 1 2
 
276.A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?
 

Diabetes Obes Metab. 2020 Sep 18. doi: 10.1111/dom.14196. Online ahead of print.

Rebecca K Vincent # 1, David M Williams # 2, Marc Evans 2
 
277.Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows
 

Semin Liver Dis. 2020 Sep 9. doi: 10.1055/s-0040-1709491. Online ahead of print.

Ian A Rowe 1 2 3
 
278.Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare
 

Dig Dis Sci. 2020 Sep 7. doi: 10.1007/s10620-020-06588-6. Online ahead of print.

Gabrielle Ritaccio 1, Gianna Stoleru 1, Ameer Abutaleb 2, Raymond K Cross 2, Kirti Shetty 2, Sasan Sakiani 2, Uni Wong 3
 
279.A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD
 

Obesity (Silver Spring). 2020 Sep 6. doi: 10.1002/oby.22964. Online ahead of print.

Mary P Moore # 1 2, Rory P Cunningham # 1 2, Ryan J Dashek 1 3, Justine M Mucinski 2, R Scott Rector 1 2 4
 
280.Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
 

Clin Gastroenterol Hepatol. 2020 Aug 31;S1542-3565(20)31220-9.doi: 10.1016/j.cgh.2020.08.061. Online ahead of print.

Jonathan G Stine, Nagambika Munaganuru, Abbey Barnard, Jennifer L Wang, Kellee Kaulback, Curtis K Argo, Siddarth Singh, Kathryn J Fowler, Claude B Sirlin, Rohit Loomba
 
281.Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers
 

J Clin Med Res. 2020 Aug;12(8):472-482. doi: 10.14740/jocmr3932. Epub 2020 Jul 22.

Ebenezer T Oni 1, Vincent Figueredo 2, Ehimen Aneni 3, Emir Veladar 4, John W McEvoy 5, Michael J Blaha 5 6, Roger S Blumenthal 5, Raquel D Conceicao 7, Jose A M Carvalho 7, Raul D Santos 7 8, Khurram Nasir 9
 
282.Improvement in Insulin Resistance and Estimated Hepatic Steatosis and Fibrosis after Endoscopic Sleeve Gastroplasty
 

Gastrointest Endosc. 2020 Aug 27;S0016-5107(20)34733-7. doi:10.1016/j.gie.2020.08.023.Online ahead of print.

Kaveh Hajifathalian 1, Amit Mehta 1, Bryan Ang 2, Daniel Skaf 2, Shawn Shah 1, Monica Saumoy 3, Qais Dawod 1, Enad Dawod 2, Alpana Shukla 4, Louis Aronne 4, Robert Brown 1, David Cohen 1, Andrew J Dannenberg 5, Brett Fortune 1, Sonal Kumar 1, Reem Z Sharaiha 6
 
283.Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging
 

Alzheimers Dement (N Y). 2020 Aug 24;6(1):e12065.doi: 10.1002/trc2.12065. eCollection 2020.

Vincenzo Solfrizzi 1, Emanuele Scafato 2 3, Carlo Custodero 1, Francesca Loparco 1, Alessandro Ciavarella 1, Francesco Panza 4 5, Davide Seripa 4 6, Bruno Pietro Imbimbo 7, Madia Lozupone 8, Nicola Napoli 1, Giuseppina Piazzolla 1, Lucia Galluzzo 3, Claudia Gandin 2, Marzia Baldereschi 9, Antonio Di Carlo 9, Domenico Inzitari 9 10, Alberto Pilotto 1 11, Carlo Sabbà 1, Italian Longitudinal Study on Aging Working Group
 
284.Tackling NAFLD: Three Targeted Populations
 

Hepatology. 2020 Aug 31. doi: 10.1002/hep.31533. Online ahead of print.

Kara Wegermann 1, Ayako Suzuki 1 2, Alisha M Mavis 3, Manal F Abdelmalek 1, Anna Mae Diehl 1, Cynthia A Moylan 1 2
 
285.Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD
 

Front Endocrinol (Lausanne). 2020 Jul 31;11:505. doi: 10.3389/fendo.2020.00505.eCollection 2020.

Annelise M Poss 1, Scott A Summers 1
 
286.NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes
 

J Diabetes Complications. 2020 Jul 17;107684. doi: 10.1016/j.jdiacomp.2020.107684.Online ahead of print.

Rosa Lombardi 1, Lorena Airaghi 2, Giovanni Targher 3, Gaetano Serviddio 4, Gabriele Maffi 2, Alessandro Mantovani 3, Claudio Maffeis 5, Antonio Colecchia 6, Rosanna Villani 4, Luca Rinaldi 7, Emanuela Orsi 8, Giuseppina Pisano 2, Luigi Elio Adinolfi 7, Silvia Fargion 2, Anna Ludovica Fracanzani 2
 
287.Mechanisms of nonalcoholic fatty liver disease and implications for surgery
 

Langenbecks Arch Surg. 2020 Aug 24. doi: 10.1007/s00423-020-01965-1.Online ahead of print.

Benedikt Kaufmann 1 2, Agustina Reca 1, Baocai Wang 2, Helmut Friess 2, Ariel E Feldstein 1, Daniel Hartmann 3
 
288.Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic
 

JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169.Epub 2020 Aug 4.

Tobias Boettler 1, Thomas Marjot 2, Philip N Newsome 3 4, Mario U Mondelli 5, Mojca Maticic 6 7, Elisa Cordero 8, Rajiv Jalan 9, Richard Moreau 10 11, Markus Cornberg 12 13, Thomas Berg 14
 
289.Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program
 

PLoS One. 2020 Aug 25;15(8):e0237430.doi: 10.1371/journal.pone.0237430. eCollection 2020.

Marina Serper 1 2 3, Marijana Vujkovic 1, David E Kaplan 1 2, Rotonya M Carr 1 2, Kyung Min Lee 4 5 6, Qing Shao 4, Donald R Miller 4, Peter D Reaven 7, Lawrence S Phillips 8 9, Christopher J O'Donnell 10 11, James B Meigs 12, Peter W F Wilson 8 9, Rachel Vickers-Smith 13, Henry R Kranzler 13 14, Amy C Justice 15 16 17, John M Gaziano 10 18, Sumitra Muralidhar 19, Saiju Pyarajan 10 11, Scott L DuVall 6 20, Themistocles L Assimes 21 22, Jennifer S Lee 21 22, Philip S Tsao 21 22, Daniel J Rader 2 23 24 25, Scott M Damrauer 1 26, Julie A Lynch 6 27, Danish Saleheen 1 28, Benjamin F Voight 1 23 29, Kyong-Mi Chang 1 2, VA Million Veteran Program
 
290.History of Nonalcoholic Fatty Liver Disease
 

Int J Mol Sci. 2020 Aug 16;21(16):E5888. doi: 10.3390/ijms21165888.

Amedeo Lonardo 1, Simona Leoni 2, Khalid A Alswat 3, Yasser Fouad 4
 
291.Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic
 

Hepatology. 2020 Aug 14;10.1002/hep.31522. doi: 10.1002/hep.31522. Online ahead of print.

Naim Alkhouri 1, Anita Kohli 1, Rohit Loomba 2, Stephen A Harrison 3
 
292.The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis
 

Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523. Online ahead of print.

Rohit Loomba 1, Lei Ling 2, Duy M Dinh 3, Alex M DePaoli 2, Hsiao D Lieu 2, Stephen A Harrison 4 5, Arun J Sanyal 6
 
293.Anti-inflammatory Activities of Green Tea Catechins along the Gut-liver Axis in Nonalcoholic Fatty Liver Disease: Lessons Learned from Preclinical and Human Studies
 

J Nutr Biochem. 2020 Aug 12;108478. doi: 10.1016/j.jnutbio.2020.108478.Online ahead of print.

Joanna K Hodges 1, Geoffrey Y Sasaki 1, Richard S Bruno 2
 
294.Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
 

J Hepatocell Carcinoma. 2020 Jul 30;7:107-116. doi: 10.2147/JHC.S252506.eCollection 2020.

Claudia Campani # 1, Carolina Bensi # 1, Stefano Milani 1, Andrea Galli 1, Mirko Tarocchi 1
 
295.Racial and Socioeconomic Disparities in Hospitalization of Pediatrics with Liver Disease from 2005 to 2015
 

Dig Dis Sci. 2020 Aug 14. doi: 10.1007/s10620-020-06530-w. Online ahead of print.

Melissa Martin 1, Biyao Zou 2, Joseph Hoang 2, Donghak Jeong 2, Rachel Bensen 1, Mindie H Nguyen 3
 
296.Trimethylamine N-Oxide levels are associated with NASH in obese subjects with type 2 diabetes
 

Diabetes Metab. 2020 Aug 10;S1262-3636(20)30102-6. doi: 10.1016/j.diabet.2020.07.010.Online ahead of print.

Paola León-Mimila 1, Hugo Villamil-Ramírez 2, Xinmin S Li 3, Diana M Shih 1, Simon T Hui 1, Elvira Ocampo-Medina 2, Blanca López-Contreras 2, Sofía Morán-Ramos 4, Marisol Olivares-Arevalo 2, Paula Grandini-Rosales 2, Luis Macías-Kauffer 2, Israel González-González 5, Rogelio Hernández-Pando 6, Francisco Gómez-Pérez 7, Francisco Campos-Pérez 5, Carlos Aguilar-Salinas 8, Elena Larrieta-Carrasco 9, Teresa Villarreal-Molina 10, Zeneng Wang 3, Aldons J Lusis 1, Stanley L Hazen 11, Adriana Huertas-Vazquez 12, Samuel Canizales-Quinteros 13
 
297.Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy
 

Surg Obes Relat Dis. 2020 Jul 14;S1550-7289(20)30411-1. doi: 10.1016/j.soard.2020.07.009.Online ahead of print.

Sébastien Frey 1, Stéphanie Patouraux 2, Tarek Debs 3, Jean Gugenheim 4, Rodolphe Anty 5, Antonio Iannelli 6
 
298.Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials
 

Cureus. 2020 Jul 6;12(7):e9018. doi: 10.7759/cureus.9018.

Muhammad Usman 1 2, Nabiyah Bakhtawar 3
 
299.NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment
 

Endocrinology. 2020 Aug 10;bqaa134.doi: 10.1210/endocr/bqaa134. Online ahead of print.

Johanna K DiStefano 1
 
300.Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
 

Gastroenterology. 2020 Aug 8;S0016-5085(20)35018-6. doi: 10.1053/j.gastro.2020.08.004.Online ahead of print.

Stephen A Harrison 1, Guy Neff 2, Cynthia D Guy 3, Mustafa R Bashir 4, Angelo H Paredes 5, Juan P Frias 6, Ziad Younes 7, James F Trotter 8, Nadege T Gunn 9, Sam E Moussa 10, Anita Kohli 11, Kristin Nelson 12, Mildred Gottwald 12, William C G Chang 12, Andrew Z Yan 12, Alex M DePaoli 12, Lei Ling 13, Hsiao D Lieu 12
 
301.Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future
 

Cell Host Microbe. 2020 Aug 12;28(2):233-244. doi: 10.1016/j.chom.2020.07.007.

Sonja Lang 1, Bernd Schnabl 2
 
302.A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
 

Lancet Gastroenterol Hepatol. 2020 Aug 4;S2468-1253(20)30252-1.doi: 10.1016/S2468-1253(20)30252-1. Online ahead of print.

Stephen A Harrison 1, Vlad Ratziu 2, Jérôme Boursier 3, Sven Francque 4, Pierre Bedossa 5, Zouher Majd 6, Geneviève Cordonnier 6, Fouad Ben Sudrik 6, Raphael Darteil 7, Roman Liebe 8, Jérémy Magnanensi 6, Yacine Hajji 6, John Brozek 6, Alice Roudot 6, Bart Staels 9, Dean W Hum 6, Sophie Jeannin Megnien 10, Suneil Hosmane 6, Noémie Dam 6, Pierre Chaumat 6, Rémy Hanf 11, Quentin M Anstee 12, Arun J Sanyal 13
 
303.Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
 

Hepatol Commun. 2020 May 19;4(8):1136-1148. doi: 10.1002/hep4.1534. eCollection 2020 Aug.

Pegah Golabi 1, James M Paik 1, Tamoore Arshad 2, Youssef Younossi 3, Alita Mishra 2, Zobair M Younossi 1 2
 
304.The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development
 

Physiol. 2020 Jul 3;11:767. doi: 10.3389/fphys.2020.00767. eCollection 2020.

Rory P Cunningham 1 2, Ryan D Sheldon 3, R Scott Rector 1 2 4
 
305.Non-invasive diagnostic tools for pediatric NAFLD: where are we now?
 

Expert Rev Gastroenterol Hepatol. 2020 Jul 25.doi: 10.1080/17474124.2020.1801413.Online ahead of print.

Antonella Mosca 1, Nadia Panera 2, Annalisa Crudele 2, Anna Alisi 2
 
306.Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone
 

BMJ Open. 2020 Jul 6;10(7):e035596. doi: 10.1136/bmjopen-2019-035596.

Daniel Bradshaw 1, Yvonne Gilleece 2, Sumita Verma 3, Iga Abramowicz 3, Stephen Bremner 3, Nicky Perry 3
 
307.A Description of Risk Factors for Non-alcoholic Fatty Liver Disease in the Southern Community Cohort Study: A Nested Case-Control Study
 

Front Nutr. 2020 May 21;7:71. doi: 10.3389/fnut.2020.00071. eCollection 2020.

Sudipa Sarkar 1, Loren Lipworth 2 3, Edmond K Kabagambe 2 3, Aihua Bian 3 4, Thomas G Stewart 4, William J Blot 2 5, T Alp Ikizler 3 6, Adriana M Hung 3 6
 
308.Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study
 

Nutrients. 2020 Jul 18;12(7):E2141. doi: 10.3390/nu12072141.

Mikiko Watanabe 1, Renata Risi 1, Elisabetta Camajani 1, Savina Contini 1, Agnese Persichetti 1, Dario Tuccinardi 2, Ilaria Ernesti 3, Stefania Mariani 1, Carla Lubrano 1, Alfredo Genco 3, Giovanni Spera 1, Lucio Gnessi 1, Sabrina Basciani 1
 
309.Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis
 

J Neuroimaging. 2020 Jul 23. doi: 10.1111/jon.12728. Online ahead of print.

Thao T Tran 1, Ke Wei 1, Soren Cole 1, Edward Mena 2, Marie Csete 1, Kevin S King 1
 
310.Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
 

J Hepatol. 2020 Jun 28;S0168-8278(20)30399-8. doi: 10.1016/j.jhep.2020.06.025.Online ahead of print.

Beth A Davison 1, Stephen A Harrison 2, Gad Cotter 3, Naim Alkhouri 4, Arun Sanyal 5, Christopher Edwards 3, Jerry R Colca 6, Julie Iwashita 6, Gary G Koch 7, Howard C Dittrich 6
 
311.Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis
 

Aliment Pharmacol Ther. 2020 Jul 8. doi: 10.1111/apt.15935. Online ahead of print.

Margery A Connelly 1, Jonathan Velez Rivera 2, John R Guyton 2, Mohammad Shadab Siddiqui 3, Arun J Sanyal 3
 
312.Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
 

Clin Mol Hepatol. 2020 Jul 17. doi: 10.3350/cmh.2020.0067. Online ahead of print.

Theresa J Hydes 1, Sujan Ravi 1, Rohit Loomba 2, Meagan E Gray 1
 
313.Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases
 

Ethan M Weinberg 1, Huy N Trinh 2, Roberto J Firpi 3, Kalyan Ram Bhamidimarri 4, Samuel Klein 5, Jonathan Durlam 6, Stephanie Watkins 6, K Rajender Reddy 1, Michael Weiss 7, Richard C Zink 6, Anna S Lok 8

Clin Gastroenterol Hepatol. 2020 Jul 3;S1542-3565(20)30930-7. doi:10.1016/j.cgh.2020.06.066.Online ahead of print.

 
 
314.Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices
 

Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.

Zobair M Younossi 1, Kathleen E Corey 2, Naim Alkhouri 3, Mazen Noureddin 4, Ira Jacobson 5, Brian Lam 1, Stephen Clement 1, Rita Basu 6, Stuart Gordon 7, Natarajan Ravendhra 8, Puneet Puri 9, Mary Rinella 10, Peter Scudera 1, Ashwani K Singal 11, Linda Henry 12, US Members of the Global Nash Council
 
315.Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial
 

Am J Gastroenterol. 2020 Jul;115(7):1055-1065. doi: 10.14309/ajg.0000000000000661.

Laura Craven 1, Adam Rahman 2 3, Seema Nair Parvathy 4, Melanie Beaton 2 3, Justin Silverman 5, Karim Qumosani 2 3, Irene Hramiak 2 6, Rob Hegele 2 6 7, Tisha Joy 2 6, Jon Meddings 8, Brad Urquhart 2, Ruth Harvie 9, Charles McKenzie 2 7, Kelly Summers 1 2, Gregor Reid 1 2 9, Jeremy P Burton 1 2 9, Michael Silverman 1 2 4
 
316.Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes
 

Diabet Med. 2020 Jul 3. doi: 10.1111/dme.14356. Online ahead of print.

T J Hydes 1, N Summers 2, E Brown 3 4, U Alam 3 4 5, H Thomaides-Brears 6, J P H Wilding 3 4, D J Cuthbertson 3 4
 
317.Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
 

Hepatol Int. 2020 Jul 4;1-11.doi: 10.1007/s12072-020-10072-8. Online ahead of print.

Shiv Kumar Sarin 1, Ashok Choudhury 2, George K Lau 3, Ming-Hua Zheng 3 4, Dong Ji 3 5, Sherief Abd-Elsalam 6, Jaeseok Hwang 7, Xiaolong Qi 8, Ian Homer Cua 9, Jeong Ill Suh 10, Jun Gi Park 10, Opass Putcharoen 11, Apichat Kaewdech 12, Teerha Piratvisuth 12, Sombat Treeprasertsuk 11, Sooyoung Park 13, Salisa Wejnaruemarn 11, Diana A Payawal 14, Oidov Baatarkhuu 15, Sang Hoon Ahn 16, Chang Dong Yeo 16, Uzziel Romar Alonzo 14, Tserendorj Chinbayar 17, Imelda M Loho 18, Osamu Yokosuka 19, Wasim Jafri 20, Soeksiam Tan 21, Lau Ing Soo 21, Tawesak Tanwandee 22, Rino Gani 23, Lovkesh Anand 24, Eslam Saber Esmail 6, Mai Khalaf 6, Shahinul Alam 25, Chun-Yu Lin 26, Wan-Long Chuang 26, A S Soin 27, Hitendra K Garg 28, Kemal Kalista 29, Badamnachin Batsukh 15, Hery Djagat Purnomo 30, Vijay Pal Dara 31, Pravin Rathi 32, Mamun Al Mahtab 25, Akash Shukla 33, Manoj K Sharma 2, Masao Omata 34 35, APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)
 
318.Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2020 Jun 29;9(7):E2032. doi: 10.3390/jcm9072032.

Lauren A Newman 1, Michael J Sorich 1, Andrew Rowland 1

 
 
319.Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score
 

Hepatol Commun.. 2020 May 26;4(7):998-1011. doi: 10.1002/hep4.1524. eCollection 2020 Jul.

Stuart C Gordon 1, Nandita Kachru 2, Emily Parker 3, Stephanie Korrer 3, A Burak Ozbay 2, Robert J Wong 4
 
320.Evolving Role for Pharmacotherapy in NAFLD/NASH
 

Clin Transl Sci. 2020 Jun 25. doi: 10.1111/cts.12839. Online ahead of print.

Suzanna L Attia 1, Samir Softic 1 2 3, Marialena Mouzaki 4
 
321.Nonalcoholic Fatty Liver Disease (NAFLD) Is an Independent Risk Factor for Nephrolithiasis in Women: Findings From NHANES III
 

J Endourol. 2020 Jun 22.doi: 10.1089/end.2020.0486. Online ahead of print.

Rourke Douglas Decker 1, Eric M Ghiraldi 2, Alexandra H Weiss 3, John P Gaughan 4, Justin I Friedlander 5 6
 
322.Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis
 

Front Physiol. 2020 Jun 3;11:551. doi: 10.3389/fphys.2020.00551. eCollection 2020.

Geraldine F Clough 1, Andrew J Chipperfield 2, Marjola Thanaj 2, Eleonora Scorletti 1 3 4, Philip C Calder 1 3, Christopher D Byrne 1 3
 
323.Cirrhosis in a Young Child Due to Fatty Liver; Importance of Early Screening: A Case Report and Review of the Literature
 

Am J Case Rep. 2020 Jun 25;21:e923250. doi: 10.12659/AJCR.923250.

Hamza Hassan Khan 1, Christine E Klingert 1 2, Sanjay Kumar 2 3, Hernando Lyons 2 3
 
324.COVID-19 and Nonalcoholic Fatty Liver Disease: Two Intersecting Pandemics
 

Eur J Clin Invest. 2020 Jun 26;e13338. doi: 10.1111/eci.13338. Online ahead of print.

Piero Portincasa 1, Marcin Krawczyk 2 3, Wiktor Smyk 4, Frank Lammert 2, Agostino Di Ciaula 1
 
325.A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
 

Ann Pharmacother. 2020 Jun 22;1060028020935105. doi: 10.1177/1060028020935105.Online ahead of print.

John A Dougherty 1, Erenie Guirguis 1, Krisy-Ann Thornby 1
 
326.Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
 

Gastroenterol Hepatol. 2020 Jun 9;S1542-3565(20)30775-8.doi: 10.1016/j.cgh.2020.05.064. Online ahead of print.

Zobair M Younossi 1, Maria Stepanova 2, Janus Ong 3, Greg Trimble 4, Saleh AlQahtani 5, Issah Younossi 2, Aijaz Ahmed 6, Andrei Racila 7, Linda Henry 2
 
327.Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results From Randomized Phase III STELLAR Trials
 

Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.

Stephen A Harrison 1, Vincent Wai-Sun Wong 2, Takeshi Okanoue 3, Natalie Bzowej 4, Raj Vuppalanchi 5, Ziad Younes 6, Anita Kohli 7, Shiv Sarin 8, Stephen H Caldwell 9, Naim Alkhouri 10, Mitchell L Shiffman 11, Marianne Camargo 12, Georgia Li 12, Kathryn Kersey 12, Catherine Jia 12, Yanni Zhu 12, C Stephen Djedjos 12, G Mani Subramanian 12, Robert P Myers 12, Nadege Gunn 13, Aasim Sheikh 14, Quentin M Anstee 15, Manuel Romero-Gomez 16, Michael Trauner 17, Zachary Goodman 18, Eric J Lawitz 10, Zobair Younossi 18, STELLAR-3 and STELLAR-4 Investigators
 
328.Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record
 

Dig Dis Sci. 2020 Jun 13. doi: 10.1007/s10620-020-06388-y. Online ahead of print.

Christopher J Danford 1, Jennifer Y Lee 2, Ian A Strohbehn 3, Kathleen E Corey 3, Michelle Lai 4
 
329.From NAFLD to MAFLD: Implications of a Premature Change in Terminology
 

Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.

Zobair M Younossi 1 2, Mary E Rinella 3, Arun Sanyal 4, Stephen A Harrison 5, Elizabeth Brunt 6, Zachary Goodman 1 2, David E Cohen 7, Rohit Loomba 8
 
330.Novel Antisense Inhibition of Diacylglycerol O-acyltransferase 2 for Treatment of Non-Alcoholic Fatty Liver Disease: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial
 

Lancet Gastroenterol Hepatol. 2020 Jun 15;S2468-1253(20)30186-2.doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.

Rohit Loomba 1, Erin Morgan 2, Lynnetta Watts 2, Shuting Xia 2, Lisa A Hannan 2, Richard S Geary 2, Brenda F Baker 2, Sanjay Bhanot 2
 
331.Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Youth
 

J Clin Endocrinol Metab. 2020 Jun 19;dgaa382. doi: 10.1210/clinem/dgaa382.Online ahead of print.

Ayesha Monga Kravetz 1 2, Todd Testerman 3, Brittany Galuppo 2, Joerg Graf 3, Bridget Pierpont 2, Stephan Siebel 2, Richard Feinn 1, Nicola Santoro 2 4
 
332.Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of Obesity in Children of Predominantly Hispanic/Latino Ancestry by Causal Mediation Analysis
 

PLoS One. 2020 Jun 22;15(6):e0234985. doi: 10.1371/journal.pone.0234985. eCollection 2020.

Presley H Nichols 1, Yue Pan 2, Benjamin May 3, Martina Pavlicova 2, John C Rausch 1 4, Ali A Mencin 4, Vidhu V Thaker 4
 
333.Non-alcoholic Fatty Liver Disease in Pregnancy Is Associated With Adverse Maternal and Perinatal Outcomes
 

J Hepatol. 2020 Apr 15;S0168-8278(20)30215-4. doi: 10.1016/j.jhep.2020.03.049.Online ahead of print.

Monika Sarkar 1, Joshua Grab 2, Jennifer L Dodge 3, Erica P Gunderson 4, Jessica Rubin 5, Roxanna A Irani 6, Marcelle Cedars 7, Norah Terrault 8
 
334.Use of Metabolic Syndrome Severity to Assess Treatment With Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis
 

Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15131. Online ahead of print.

Matthew J Gurka 1, Jasmine A Mack 1, Xiaofei Chi 1, Mark D DeBoer 2
 
335.Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
 

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt 1, David Petroff 2, Valentin Blank 1 3, Albrecht Böhlig 1, Florian van Bömmel 1, Christian Wittekind 4, Thomas Berg 1, Thomas Karlas 1, Johannes Wiegand 1
 
336.Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Where Do Diabetologists Stand?
 

Clin Diabetes Endocrinol. 2020 Jun 5;6:9. doi: 10.1186/s40842-020-00097-1.eCollection 2020.

Shaheen Tomah 1 2, Naim Alkhouri 3, Osama Hamdy 1 2
 
337.Prediction of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease Using Gut Microbiota-Based Approaches Compared With Simple Non-Invasive Tools
 

Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0.

Sonja Lang 1 2, Fedja Farowski 3 4 5, Anna Martin 1, Hilmar Wisplinghoff 6 7 8, Maria J G T Vehreschild 3 4 5, Marcin Krawczyk 9 10, Angela Nowag 6 8, Anne Kretzschmar 6, Claus Scholz 6, Philipp Kasper 1, Christoph Roderburg 11, Frank Lammert 9, Tobias Goeser 1, Hans-Michael Steffen 1, Münevver Demir 12 13
 
338.Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai
 

Hawaii J Health Soc Welf. 2020 Jun 1;79(6):180-186.

Robert J Pattison 1, James Phillip Esteban 2, Tomoki Sempokuya 3, Jakrin Kewcharoen 1, Sumodh Kalathil 4, Scott K Kuwada 5
 
339.Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future
 

Semin Liver Dis. 2020 Jun 11. doi: 10.1055/s-0040-1713006. Online ahead of print.

Leon A Adams 1 2, Wah-Kheong Chan 3
 
340.Burden of Nonalcoholic Fatty Liver Disease in Canada, 2019-2030: A Modelling Study
 

 

CMAJ Open. 2020 Jun 9;8(2):E429-E436. doi: 10.9778/cmajo.20190212. Print Apr-Jun 2020.

Mark G Swain 1, Alnoor Ramji 1, Keyur Patel 1, Giada Sebastiani 1, Abdel Aziz Shaheen 1, Edward Tam 1, Paul Marotta 1, Magdy Elkhashab 1, Harpreet S Bajaj 1, Chris Estes 2, Homie Razavi 1

 

 
 
341.Utilization of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis
 

Hepatology. 2020 May 8.doi: 10.1002/hep.31309. Online ahead of print.

Erin Wolf 1, Nicole E Rich 1, Jorge A Marrero 1, Neehar Parikh 2, Amit G Singal 1
 
342.Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies
 

Clin Exp Hepatol. May-Jun 2020;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy 1, Hemnishil K Marella 1, Yu Jiang 2, Surosree Ganguli 3, Peter Snell 1, Pradeep S B Podila 4, Benedict Maliakkal 1, Sanjaya K Satapathy 5
 
343.Advances in Non-Invasive Biomarkers for the Diagnosis and Monitoring of Non-Alcoholic Fatty Liver Disease
 

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long 1, Sanil Gandhi 2, Rohit Loomba 3
 
344.Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
 

Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413. Online ahead of print.

Ruth M Pfeiffer 1, Yaron Rotman 2, Thomas R O'Brien 1
 
345.Comparison of MAFLD and NAFLD Diagnostic Criteria in Real World
 

Liver Int .2020 Jun 1. doi: 10.1111/liv.14548. Online ahead of print.

Su Lin 1, Jiaofeng Huang 1, Mingfang Wang 1, Rahul Kumar 2, Yuxiu Liu 1, Shiying Liu 1, Yinlian Wu 1, Xiaozhong Wang 3, Yueyong Zhu 1
 
346.Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
 

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour 1 2, Cyrielle Caussy 3 4, Rohit Loomba 5
 
347.Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis
 

Aliment Pharmacol Ther. 2020 Jun;51(12):1305-1320. doi: 10.1111/apt.15738.Epub 2020 May 7.

Björn Carlsson 1, Daniel Lindén 1 2, Gabriella Brolén 3, Mathias Liljeblad 1, Mikael Bjursell 1, Stefano Romeo 4 5 6, Rohit Loomba 7
 
348.Increased Atherogenic Lipoprotein Profile in Children With Non-Alcoholic Steatohepatitis
 

Pediatr Obes. 2020 May 4;e12648 doi: 10.1111/ijpo.12648. Online ahead of print.

Eduardo Castillo-Leon 1, Margery A Connelly 2, Juna V Konomi 1, Shelley Caltharp 3 4, Rebecca Cleeton 1, Miriam B Vos 1 4 5
 
349.Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease Are Major Drivers of Liver Mortality in the United States
 

Hepatol Commun. 2020 Apr 4;4(6):890-903. doi: 10.1002/hep4.1510. eCollection 2020 Jun.

James M Paik 1, Pegah Golabi 1, Rakesh Biswas 1, Saleh Alqahtani 2, Chapy Venkatesan 1, Zobair M Younossi 1 3
 
350.Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality
 

Am J Gastroenterol. 2020 Jun 3. doi: 10.14309/ajg.0000000000000654. Online ahead of print.

Donghee Kim 1, Luis Miguel Vazquez-Montesino 2, Jessica A Escober 1, Christopher T Fernandes 1, George Cholankeril 1, Rohit Loomba 3 4, Stephen A Harrison 5 6, Zobair M Younossi 7, Aijaz Ahmed 1
 
351.Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
 

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt 1, David Petroff 2, Valentin Blank 1 3, Albrecht Böhlig 1, Florian van Bömmel 1, Christian Wittekind 4, Thomas Berg 1, Thomas Karlas 1, Johannes Wiegand 1
 
352.Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum
 

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9.doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
 
353.Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial
 

Gastroenterol. 2020 May 15. doi: 10.14309/ajg.0000000000000661. Online ahead of print.

Laura Craven 1, Adam Rahman 2 3, Seema Nair Parvathy 4, Melanie Beaton 2 3, Justin Silverman 5, Karim Qumosani 2 3, Irene Hramiak 2 6, Rob Hegele 2 6 7, Tisha Joy 2 6, Jon Meddings 8, Brad Urquhart 2, Ruth Harvie 9, Charles McKenzie 2 7, Kelly Summers 1 2, Gregor Reid 1 2 9, Jeremy P Burton 1 2 9, Michael Silverman 1 2 4
 
354.Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease
 

Gastroenterol. 2020 May 25. doi: 10.14309/ajg.0000000000000676. Online ahead of print.

Ramy Younes 1 2, Olivier Govaere 2, Salvatore Petta 3, Luca Miele 4 5, Dina Tiniakos 2, Alastair Burt 2, Ezio David 6, Fabio M Vecchio 4 7, Marco Maggioni 8, Daniela Cabibi 9, Anna L Fracanzani 10, Chiara Rosso 1, Maria J Garcia Blanco 11, Angelo Armandi 1, Gian Paolo Caviglia 1, Marco Y W Zaki 2 12, Antonio Liguori 4, Paolo Francione 10, Grazia Pennisi 3, Antonio Grieco 4 5, Luca Valenti 13, Quentin M Anstee 2 14, Elisabetta Bugianesi 1
 
355.Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data
 

Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5.

Rohit Loomba 1 2, Robert Wong 3, Jeremy Fraysse 4, Sanatan Shreay 4, Suying Li 5, Stephen Harrison 6, Stuart C Gordon 7
 
356.Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis
 

Hepatology. 2020 May 16.doi: 10.1002/hep.31317. Online ahead of print.

Kimberly P Newton 1 2, Joel E Lavine 3, Laura Wilson 4 5, Cynthia Behling 6 7, Miriam B Vos 8, Jean P Molleston 9, Philip Rosenthal 10, Tamir Miloh 11, Mark H Fishbein 12, Ajay K Jain 13, Karen F Murray 14, Jeffrey B Schwimmer 1 2, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN): 

Donna Garner, Paula Hertel, Ryan Himes, Alicia Lawson, Tamir Miloh, Nicole Triggs, Kristin Bramlage, April Carr, Kim Cecil, Meghan McNeill, Marialena Mouzaki, Andrew Trout, Stavra Xanthakos, Kimberlee Bernstein, Stephanie DeVore, Rohit Kohli, Kathleen Lake, Daniel Podberesky, Alex Towbin, Joel E Lavine, Ali Mencin, Elena Reynoso, Adina Alazraki, Rebecca Cleeton, Maria Cordero, Albert Hernandez, Saul Karpen, Jessica Cruz Munos, Nicholas Raviele, Miriam Vos, Molly Bozic, Laura Carr, Oscar W Cummings, Kathryn Harlow, Ann Klipsch, Jean P Molleston, Emily Ragozzino, Girish Rao, Kimberly Kafka, Ann Scheimann, Mark H Fishbein, Saeed Mohammad, Peter F Whitington, Sarah Barlow, Elizabeth M Brunt, Danielle Carpenter, Theresa Cattoor, Jose Derdoy, Janet Freebersyser, Ajay Jain Debra King, Jinping Lai, Joan Siegner, Susan Stewart, Susan Torretta, Kristina Wriston, Jennifer Arin, Cynthia Behling, Craig Bross, Carissa Carrier, Diana De La Pena, Janis Durelle, Mary Catherine Huckaby, Michael S Middleton, Kimberly Newton, Jeffrey B Schwimmer, Claude Sirlin, Patricia Ugalde-Nicalo, Jesse Courtier, Ryan Gill, Camille Langlois, Emily Rothbaum Perito, Philip Rosenthal, Patrika Tsai, Niviann Blondet, Kara Cooper, Karen Murray, Randolph Otto, Matthew Yeh, Melissa Young, Elizabeth M Brunt, Kathryn Fowler, David E Kleiner, Edward C Doo, Sherry Hall, Jay H Hoofnagle, Patricia R Robuck, Averell H Sherker, Rebecca Torrance, Patricia Belt, Jeanne M Clark, John Dodge, Michele Donithan, Milana Isaacson, Mariana Lazo, Jill Meinert, Laura Miriel, Emily P Sharkey, Jacqueline Smith, Michael Smith, Alice Sternberg, James Tonascia, Mark L Van Natta, Annette Wagoner, Laura A Wilson, Goro Yamada, Katherine P Yates
 
357.Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research
 

Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo 1, Ayako Suzuki 2
 
358.Evolving Aspects of Liver Transplantation for Nonalcoholic Steatohepatitis
 

Curr Opin Organ Transplant. 2013 Jun;18(3):251-8.doi: 10.1097/MOT.0b013e3283615d30.

Michael Charlton 1
 
359.Non-alcoholic Liver Disease and Childhood Obesity
 

Arch Dis Child. 2020 May 14;archdischild-2019-318063.doi: 10.1136/archdischild-2019-318063. Online ahead of print.

Meera Shaunak 1, Christopher D Byrne 2 3, Nikki Davis 1 2, Paul Afolabi 2 3, Saul N Faust 2 3 4, Justin Huw Davies 5 2
 
360.Decompensated Cirrhosis Is the Commonest Presentation for NAFLD Patients Undergoing Liver Transplant Assessment
 

Clin Med (Lond). 2020 May;20(3):313-318. doi: 10.7861/clinmed.2019-0250.

Ahmed Hussain 1, Preya J Patel 1, Freya Rhodes 1, Ankur Srivastava 1, David Patch 1, William Rosenberg 2
 
361.Risk Stratification of Patients With Nonalcoholic Fatty Liver Disease Using a Case Identification Pathway in Primary Care: A Cross-Sectional Study
 

MAJ Open. 2020 May 15;8(2):E370-E376.doi: 10.9778/cmajo.20200009. Print Apr-Jun 2020.

Abdel Aziz Shaheen 1, Kiarash Riazi 2, Alexandra Medellin 2, Deepak Bhayana 2, Gilaad G Kaplan 2, Jason Jiang 2, Roy Park 2, Wendy Schaufert 2, Kelly W Burak 2, Monica Sargious 2, Mark G Swain 2
 
362.The Effect of Sleep on Gastrointestinal Functioning in Common Digestive Diseases
 

Lancet Gastroenterol Hepatol. 2020 Jun;5(6):616-624.doi: 10.1016/S2468-1253(19)30412-1.

William C Orr 1, Ronnie Fass 2, Shikha S Sundaram 3, Ann O Scheimann 4
 
363.Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2020 Apr 30;S1542-3565(20)30613-3.doi: 10.1016/j.cgh.2020.04.068. Online ahead of print.

Fateh Bazerbachi 1, Eric J Vargas 2, Monika Rizk 2, Daniel B Maselli 2, Taofic Mounajjed 3, Sudhakar K Venkatesh 4, Kymberly D Watt 2, John D Port 4, Rita Basu 5, Andres Acosta 2, Ibrahim Hanouneh 2, Naveen Gara 6, Meera Shah 7, Manpreet Mundi 7, Matthew Clark 7, Karen Grothe 7, Andrew C Storm 2, Michael J Levy 2, Barham K Abu Dayyeh 8
 
364.Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis
 

Immunity. 2020 May 1;S1074-7613(20)30159-X. doi: 10.1016/j.immuni.2020.04.001.Online ahead of print.

Jason S Seidman 1, Ty D Troutman 2, Mashito Sakai 1, Anita Gola 3, Nathanael J Spann 1, Hunter Bennett 1, Cassi M Bruni 1, Zhengyu Ouyang 1, Rick Z Li 1, Xiaoli Sun 4, BaoChau T Vu 1, Martina P Pasillas 1, Kaori M Ego 1, David Gosselin 5, Verena M Link 6, Ling-Wa Chong 7, Ronald M Evans 8, Bonne M Thompson 9, Jeffrey G McDonald 9, Mojgan Hosseini 10, Joseph L Witztum 4, Ronald N Germain 3, Christopher K Glass 11
 
365.Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
 

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour 1 2, Cyrielle Caussy 3 4, Rohit Loomba 5
 
366.Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum
 

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9 doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
 
367.Antitumour Necrosis Factor-a Agents and Development of New-Onset Cirrhosis or Non-Alcoholic Fatty Liver Disease: A Retrospective Cohort
 

BMJ Open Gastroenterol. 2020 Apr 15;7(1):e000349.doi: 10.1136/bmjgast-2019-000349.eCollection 2020.

Kuo-Tung Tang 1 2 3, Jean-François Dufour 4 5, Po-Hung Chen 6, Ruben Hernaez 7 8, Susan Hutfless 6
 
368.Biomarkers of NAFLD and NASH
 

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long 1, Sanil Gandhi 2, Rohit Loomba 3
 
369.Macrophages in Metabolic Associated Fatty Liver Disease
 

World J Gastroenterol. 2020 Apr 28;26(16):1861-1878.doi: 10.3748/wjg.v26.i16.1861.

Jawaher Alharthi 1, Olivier Latchoumanin 1, Jacob George 1, Mohammed Eslam 2
 
370.Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies
 

J Clin Exp Hepatol. May-Jun 2020;10(3):245-254.doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy 1, Hemnishil K Marella 1, Yu Jiang 2, Surosree Ganguli 3, Peter Snell 1, Pradeep S B Podila 4, Benedict Maliakkal 1, Sanjaya K Satapathy 5
 
371.Blood Lead Level Is Associated With Advanced Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease: A Nationwide Survey (NHANES 2011-2016)
 

Ann Hepatol. 2020 Apr 4;S1665-2681(20)30028-4. doi: 10.1016/j.aohep.2020.03.006.Online ahead of print.

Debashis Reja 1, Aayush Visaria 2, Briette Karanfilian 3, Vinod Rustgi 4
 
372.Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis
 

Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15738. Online ahead of print.

Björn Carlsson 1, Daniel Lindén 1 2, Gabriella Brolén 3, Mathias Liljeblad 1, Mikael Bjursell 1, Stefano Romeo 4 5 6, Rohit Loomba 7
 
373.Epidemiology and Pathophysiology of the Association Between NAFLD and Metabolically Healthy or Metabolically Unhealthy Obesity
 

Ann Hepatol. 2020 Mar 21;S1665-2681(20)30023-5.doi: 10.1016/j.aohep.2020.03.001. Online ahead of print.

Amedeo Lonardo 1, Alessandro Mantovani 2, Simonetta Lugari 3, Giovanni Targher 2
 
374.The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study
 

Clin Transl Gastroenterol. 2020 Apr;11(4):e00170. doi: 10.14309/ctg.0000000000000170.

Carmen S S Latenstein 1, Louise J M Alferink 2, Sarwa Darwish Murad 2, Joost P H Drenth 3, Cornelis J H M van Laarhoven 1, Philip R de Reuver 1
 
375.Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data
 

Aliment Pharmacol Ther. 2020 May 5. doi: 10.1111/apt.15679. Online ahead of print.

Rohit Loomba 1 2, Robert Wong 3, Jeremy Fraysse 4, Sanatan Shreay 4, Suying Li 5, Stephen Harrison 6, Stuart C Gordon 7
 
376.Nutrition and Genetics in NAFLD: The Perfect Binomium
 

Int J Mol Sci. 2020 Apr 23;21(8):E2986. doi: 10.3390/ijms21082986.

Marica Meroni 1 2, Miriam Longo 1 3, Alice Rustichelli 1, Paola Dongiovanni 1
 
377.Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease
 

Curr Pharm Des. 2020 Apr 28.doi: 10.2174/1381612826666200429093648.Online ahead of print.

Francesco Tovoli 1, Silvia Ferri 2, Fabio Piscaglia 1
 
378.Thyroid Hormone Signaling and the Liver
 

Hepatology. 2020 Apr 28.doi: 10.1002/hep.31296. Online ahead of print.

Megan J Ritter 1, Izuki Amano 1 2, Anthony N Hollenberg 1
 
379.Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population
 

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner 1 2, Tamoore Arshad 1, Pegah Golabi 2, James Paik 2, Freba Farhat 1, Zobair M Younossi 3 4
 
380.How Good Are Controlled Attenuation Parameter Scores From Fibroscan to Assess Steatosis, NASH, and Fibrosis?
 

Dig Dis Sci. 2020 Apr 27.doi: 10.1007/s10620-020-06269-4. Online ahead of print.

Joshua Trowell 1, Joseph Alukal 1, Talan Zhang 1, Li Liu 2, Anurag Maheshwari 1 3, Hwan Y Yoo 1, Paul J Thuluvath 4 5
 
381.Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach
 

Metabolites. 2020 Apr 24;10(4):E168. doi: 10.3390/metabo10040168.

George N Ioannou 1 2 3, G A Nagana Gowda 4, Danijel Djukovic 4, Daniel Raftery 4 5 6
 
382.Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population
 

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner 1 2, Tamoore Arshad 1, Pegah Golabi 2, James Paik 2, Freba Farhat 1, Zobair M Younossi 3 4
 
383.Is Bariatric Surgery Resolving NAFLD via Microbiota-Mediated Bile Acid Ratio Reversal? A Comprehensive Review
 

Surg Obes Relat Dis. 2020 Mar 20;S1550-7289(20)30131-3. doi: 10.1016/j.soard.2020.03.013.Online ahead of print.

Eider Talavera-Urquijo 1, Marc Beisani 2, José M Balibrea 3, John C Alverdy 4
 
384.Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum
 

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9. doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
 
385.Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research
 

J Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo 1, Ayako Suzuki 2
 
386. Metabolic Risk Factors and Incident Advanced Liver Disease in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Population-Based Observational Studies
 

Med. 2020 Apr 30;17(4):e1003100. doi: 10.1371/journal.pmed.1003100.eCollection 2020 Apr.

Helen Jarvis 1, Dawn Craig 1, Robert Barker 1, Gemma Spiers 1, Daniel Stow 1, Quentin M Anstee 2 3, Barbara Hanratty 1
 
387.African Americans Have a Distinct Clinical and Histologic Profile With Lower Prevalence of NASH and Advanced Fibrosis Relative to Caucasians
 

Eur J Gastroenterol Hepatol. 2020 Apr 20. doi: 10.1097/MEG.0000000000001735.Online ahead of print.

Sanjaya K Satapathy 1 2, Hemnishil K Marella 3, Rajiv P Heda 3, Surosree Ganguli 4, Yala Kirthi Reddy 5, Pradeep S B Podila 1, Ian Clark 6, Benedict Maliakkal 1
 
388.Potential Implications of COVID-19 in Non-Alcoholic Fatty Liver Disease
 

Liver Int. 2020 Apr 19. doi: 10.1111/liv.14484. Online ahead of print.

Grietje H Prins 1, Peter Olinga 1
 
389.Obesity as a Risk Factor for Greater Severity of COVID-19 in Patients With Metabolic Associated Fatty Liver Disease
 

Metabolism. 2020 Apr 19;154244. doi: 10.1016/j.metabol.2020.154244. Online ahead of print.

Kenneth I Zheng 1, Feng Gao 2, Xiao-Bo Wang 3, Qing-Feng Sun 4, Ke-Hua Pan 5, Ting-Yao Wang 6, Hong-Lei Ma 1, Wen-Yue Liu 7, Jacob George 8, Ming-Hua Zheng 9
 
390.FXR Agonists as Therapy for Liver Disease
 

Hoofnagle JH1. Hepatology. 2020 Apr 10. doi: 10.1002/hep.31265. [Epub ahead of print]
 
391.Obeticholic acid for the treatment of nonalcoholic steatohepatitis
 

Shah RA1, Kowdley KV1. Expert Rev Gastroenterol Hepatol. 2020 Apr 3. doi: 10.1080/17474124.2020.1748498. [Epub ahead of print]
 
392.Bile acids associate with specific gut microbiota, low level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease
 

Adams LA1,2, Wang Z1,2, Liddle C3, Melton PE4,5, Ariff A4, Chandraratna H6, Tan J7, Ching H1, Coulter S3, de Boer B8, Christophersen CT9,10, O'Sullivan TA9, Morrison M11, Jeffrey GP1,2. Liver Int. 2020 Apr 3. doi: 10.1111/liv.14453. [Epub ahead of print]
 
393.Dietary Factors in Relation to Liver Fat Content: A Cross-sectional Study
 

Watzinger C1, Nonnenmacher T2, Grafetstätter M1, Sowah SA1,3, Ulrich CM4, Kauczor HU2, Kaaks R1, Schübel R1,2, Nattenmüller J2, Kühn T1. Nutrients. 2020 Mar 20;12(3). pii: E825. doi: 10.3390/nu12030825.
 
394.